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A B S T R A C T
Background
Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-
term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial
infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line therapy for hypertension. However, the
benefit of beta-blockers as first-line therapy for hypertension without compelling indications is controversial. This review is an update
of a Cochrane Review initially published in 2007 and updated in 2012.
Objectives
To assess the effects of beta-blockers on morbidity and mortality endpoints in adults with hypertension.
Search methods
The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to June 2016:
the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 6),
MEDLINE (from 1946), Embase (from 1974), and ClinicalTrials.gov. We checked reference lists of relevant reviews, and reference lists
of studies potentially eligible for inclusion in this review, and also searched the the World Health Organization International Clinical
Trials Registry Platform on 06 July 2015.
Selection criteria
Randomised controlled trials (RCTs) of at least one year of duration, which assessed the effects of beta-blockers compared to placebo
or other drugs, as first-line therapy for hypertension, on mortality and morbidity in adults.
Data collection and analysis
We selected studies and extracted data in duplicate, resolving discrepancies by consensus. We expressed study results as risk ratios (RR)
with 95% confidence intervals (CI) and conducted fixed-effect or random-effects meta-analyses, as appropriate. We also used GRADE
to assess the certainty of the evidence. GRADE classifies the certainty of evidence as high (if we are confident that the true effect lies
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close to that of the estimate of effect), moderate (if the true effect is likely to be close to the estimate of effect), low (if the true effect
may be substantially different from the estimate of effect), and very low (if we are very uncertain about the estimate of effect).
Main results
Thirteen RCTs met inclusion criteria. They compared beta-blockers to placebo (4 RCTs, 23,613 participants), diuretics (5 RCTs,
18,241 participants), calcium-channel blockers (CCBs: 4 RCTs, 44,825 participants), and renin-angiotensin system (RAS) inhibitors
(3 RCTs, 10,828 participants). These RCTs were conducted between the 1970s and 2000s and most of them had a high risk of bias
resulting from limitations in study design, conduct, and data analysis. There were 40,245 participants taking beta-blockers, three-
quarters of them taking atenolol. We found no outcome trials involving the newer vasodilating beta-blockers (e.g. nebivolol).
There was no difference in all-cause mortality between beta-blockers and placebo (RR 0.99, 95% CI 0.88 to 1.11), diuretics or RAS
inhibitors, but it was higher for beta-blockers compared to CCBs (RR 1.07, 95% CI 1.00 to 1.14). The evidence on mortality was of
moderate-certainty for all comparisons.
Total CVD was lower for beta-blockers compared to placebo (RR 0.88, 95% CI 0.79 to 0.97; low-certainty evidence), a reflection of
the decrease in stroke (RR 0.80, 95% CI 0.66 to 0.96; low-certainty evidence) since there was no difference in coronary heart disease
(CHD: RR 0.93, 95%CI 0.81 to 1.07; moderate-certainty evidence). The effect of beta-blockers on CVDwas worse than that of CCBs
(RR 1.18, 95% CI 1.08 to 1.29; moderate-certainty evidence), but was not different from that of diuretics (moderate-certainty) or RAS
inhibitors (low-certainty). In addition, there was an increase in stroke in beta-blockers compared to CCBs (RR 1.24, 95% CI 1.11 to
1.40; moderate-certainty evidence) and RAS inhibitors (RR 1.30, 95% CI 1.11 to 1.53; moderate-certainty evidence). However, there
was little or no difference in CHD between beta-blockers and diuretics (low-certainty evidence), CCBs (moderate-certainty evidence)
or RAS inhibitors (low-certainty evidence). In the single trial involving participants aged 65 years and older, atenolol was associated
with an increased CHD incidence compared to diuretics (RR 1.63, 95% CI 1.15 to 2.32). Participants taking beta-blockers were
more likely to discontinue treatment due to adverse events than participants taking RAS inhibitors (RR 1.41, 95% CI 1.29 to 1.54;
moderate-certainty evidence), but there was little or no difference with placebo, diuretics or CCBs (low-certainty evidence).
Authors’ conclusions
Most outcome RCTs on beta-blockers as initial therapy for hypertension have high risk of bias. Atenolol was the beta-blocker most
used. Current evidence suggests that initiating treatment of hypertension with beta-blockers leads to modest CVD reductions and little
or no effects on mortality. These beta-blocker effects are inferior to those of other antihypertensive drugs. Further research should be
of high quality and should explore whether there are differences between different subtypes of beta-blockers or whether beta-blockers
have differential effects on younger and older people.
P L A I N L A N G U A G E S U M M A R Y
Beta-blockers for hypertension
What is the aim of this review?
The aim of this Cochrane Review was to assess whether beta-blockers decrease the number of deaths, strokes, and heart attacks associated
with high blood pressure in adults. We collected and analysed all relevant studies to answer this question and found 13 relevant studies.
Are beta-blockers as good as other medicines when used for treatment of adults with high blood pressure?
Beta-blockers were not as good at preventing the number of deaths, strokes, and heart attacks as other classes of medicines such as
diuretics, calcium-channel blockers, and renin-angiotensin system inhibitors. Most of these findings come from one type of beta-blocker
called atenolol. However, beta-blockers are a diverse group of medicines with different properties, and we need more well-conducted
research in this area.
What was studied in the review?
Millions of people with high blood pressure have strokes, heart attacks, and other diseases, and many of them die. This situation could
be prevented with appropriate treatment. Researchers have tried different medicines for treating high blood pressure.
What are the main results of the review?
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We found 13 studies from high-income countries, mainly Western Europe and North America. In the studies, the people receiving
beta-blockers were compared to people who received no treatment or other medicines. The studies showed the following.
Beta-blockers probably make little or no difference in the number of deaths among people on treatment for high blood pressure. This
effect appears to be similar to that of diuretics and renin-angiotensin system inhibitors, but beta-blockers are probably not as good at
preventing deaths from high blood pressure as calcium-channel blockers.
Beta-blockers may reduce the number of strokes, an effect which appears to be similar to that of diuretics. However, beta-blockers may
not be as good at preventing strokes as renin-angiotensin system inhibitors or calcium-channel blockers.
Beta-blockers may make little or no difference to the number of heart attacks among people with high blood pressure. The evidence
suggests that this effect may not be different from that of diuretics, renin-angiotensin system inhibitors, or calcium-channel blockers.
However, among people aged 65 years and older, the evidence suggests that beta-blockers may not be as good at reducing heart attacks
as diuretics.
People given beta-blockers are more likely to have side effects and stop treatment than people taking renin-angiotensin system inhibitors,
but there may be little or no difference in side effects between beta-blockers and diuretics or calcium-channel blockers.
How up-to-date is this review?
The review authors searched for studies that had been published up to June 2016.
3Beta-blockers for hypertension (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Beta-blockers versus placebo as first- line therapy for hypertension
Participants: people with hypertension
Settings: high-income countries, mainly Western Europe and North America
Intervention: beta-blockers
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95%CI)
No of participants
(studies)
Certainty of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Beta-blockers
Total mortality 52 per 1000 51 per 1000
(46 to 57)
RR 0.99
(0.88 to 1.11)
23613
(4 studies)
⊕⊕⊕©
Moderate1
Total cardiovascular dis-
ease
64 per 1000 57 per 1000
(51 to 63)
RR 0.88
(0.79 to 0.97)
23613
(4 studies)
⊕⊕©©
Low1,2
Total stroke 23 per 1000 18 per 1000
(15 to 22)
RR 0.80
(0.66 to 0.96)
23613
(4 studies)
⊕⊕©©
Low1,2
Total coronary heart dis-
ease
37 per 1000 34 per 1000
(30 to 40)
RR 0.93
(0.81 to 1.07)
23613
(4 studies)
⊕⊕⊕©
Moderate1
Withdrawal due to adverse
effect
74 per 1000 249 per 1000
(60 to 1000)
RR 3.38
(0.82 to 13.95)
22729
(3 studies)
⊕⊕©©
Low3
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
1 The two studies that contribute to the most weight of the pooled RR have high risk of bias (especially incomplete outcome
report ing due to attrit ion bias): downgraded by 1 point.
2 The RR is too close to 1 and could easily include 1 if more trials are added: downgraded by 1 point.
3 Inconsistent results across studies (I2 = 100%): downgraded by 2 points.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Hypertension is one of the leading causes of disability and pre-
mature deaths worldwide (GBD 2015). The rationale for treat-
ing hypertension achieved great impetus with the finding that
even small reductions in blood pressure can significantly reduce
associated morbidity and mortality risks (Collins 1990; Staessen
2003; Thomopoulos 2015). The major classes of drugs for treat-
ing hypertension include beta-blockers, calcium-channel blockers
(CCBs), diuretics, and renin-angiotensin system (RAS) inhibitors
(Wiysonge 2013).
Description of the intervention
Beta-blockers refer to a diverse group of drugs which block the ac-
tion of endogenous catecholamines on beta-adrenergic receptors,
part of the autonomic (or sympathetic) nervous system (Wiysonge
2007a). The autonomic nervous system has been known to play
a role in blood pressure control since 1949 (Smithwick 1949).
The principal adrenergic receptors present in the human cardio-
vascular system are the β1, β2, and α1 receptors (Fergus 2015;
Pucci 2016). Beta-blockers vary in their β1/β2-adrenergic recep-
tor selectivity and vasodilatory properties, and this diversity has
given rise to their classification into first, second, and third gener-
ation. First-generation beta-blockers exercise identical affinity for
β1 and β2 receptors and are thus classified as non-selective beta-
blockers (e.g. propranolol). Second-generation beta-blockers are
more attracted to β1 than β2 receptors, and are thus termed se-
lective beta-blockers (e.g. atenolol). The third-generation of beta-
blockers are known for their intrinsic vasodilatory properties (e.g.
nebivolol) (Weber 2005).
How the intervention might work
Beta-blockers have been used as first-line therapy for hypertension
since the late 1960s, apparently because activation of the sympa-
thetic nervous system is important in the aetiology and mainte-
nance of hypertension (Berglund 1981; JNC-6 1997; Larochelle
2014; Philipp 1997; Psaty 1997; Ramsay 1999; Wiysonge 2013);
but the robustness of the evidence for use of beta-blockers as
first-line therapy for hypertension without compelling indica-
tions is controversial (Carlberg 2004; Khan 2006; Lindhom 2005;
Messerli 2003; Opie 1997; Opie 2014; Wiysonge 2007a; Wright
2000). From 2004 to 2006, three meta-analyses were published
which found that beta-blockers were less effective in reducing the
incidence of stroke (Lindhom 2005), and the composite of major
cardiovascular outcomes including stroke, myocardial infarction,
and death (Khan 2006), compared to all drugs for treating hyper-
tension. However, beta-blockers might have different comparative
outcomes versus the various other classes of drugs. For instance,
several studies have claimed that CCBs are better than other an-
tihypertensive agents in preventing stroke but less good at pre-
venting coronary heart disease (CHD; Angeli 2004; Opie 2002;
Verdecchia 2005). Thus, it is important to know towhat extent the
comparisons made by Lindholm and colleagues (Carlberg 2004;
Lindhom 2005) and Khan and co-authors (Khan 2006; Kuyper
2014) relate to beta-blockers versus specific classes of antihyper-
tensive drugs such as diuretics, CCBs, or RAS inhibitors. RAS in-
hibitors refer to angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers (ARBs), and direct renin inhibitors
(DRI). In general, beta-blockers might be better or worse than
one specific class of drugs for specific endpoints so that comparing
beta-blockers with all other classes could be misleading (Carlberg
2004; Lindhom 2005; Khan 2006). In addition, the safety of a
medication is as important to the clinician and the person as is
the effectiveness; but neither Lindholm and colleagues (Carlberg
2004; Lindhom 2005) nor Khan and co-authors (Khan 2006;
Kuyper 2014) provided data on this aspect when comparing beta-
blockers to other antihypertensive agents (see also Table 1).
Why it is important to do this review
Proper understanding of the evidence for beta-blocker therapy
in hypertension requires a regularly updated systematic, compre-
hensive, and appropriate analysis of all currently available data.
In 2007, we published a Cochrane Review which re-assessed the
place of beta-blockers as first-line therapy for hypertension relative
to each of the other major classes of antihypertensive drugs. An
update of the review was published in 2012. The current review
is an update of the 2012 review.
O B J E C T I V E S
To assess the effects of beta-blockers on morbidity and mortality
endpoints in adults with hypertension.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) with a duration of one year
or more.
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Types of participants
Men and non-pregnant women, aged 18 years and over, with hy-
pertension as defined by cut-off points operating at the time of
the study under consideration.
Types of interventions
The treatment groupmust have received a beta-blocker drug either
as monotherapy or as a first-line drug in a stepped-care approach.
The control group could have been a placebo, no treatment, or
another antihypertensive drug (including a different beta-blocker
or the same beta-blocker at a different dose).
Types of outcome measures
Primary outcomes
• Mortality.
Secondary outcomes
• Total (i.e. fatal and non-fatal) stroke.
• Total coronary heart disease (myocardial infarction, sudden
death).
• Total cardiovascular disease (CVD: i.e. fatal and non-fatal
CHD, stroke, congestive heart failure, and transient ischaemic
attacks).
• Adverse events leading to discontinuation of allocated
treatment.
• Degree of reduction in systolic and diastolic blood pressure
achieved by beta-blocker therapy in relation to each comparator
treatment.
We used the definitions employed by the investigators of the study
under consideration.
Search methods for identification of studies
Electronic searches
The Cochrane Hypertension Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials without language, publication year or publication sta-
tus restrictions:
• the Cochrane Hypertension Specialised Register via the
Cochrane Register of Studies (CRS-Web) (searched 14 June
2016);
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 6) via the Cochrane Register of Studies
(CRS-Web) (searched 14 June 2016);
• MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid
Epub Ahead of Print, and MEDLINE Ovid In-Process & Other
Non-Indexed Citations (searched 14 June 2016);
• Embase Ovid (searched 14 June 2016);
• ClinicalTrials.gov (www.clinicaltrials.gov) searched 14 June
2016);
The Information Specialist modelled subject strategies for
databases on the search strategy designed for MEDLINE. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled (as described in the Cochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0,
Box 6.4.b. (Handbook 2011)). Search strategies from 19 January
2015 are found in Appendix 1. Search strategies for all major
databases are provided in Appendix 2.
Searches for previous versions of the reviewwere conducted in June
2006, May 2011, December 2011, and November 2012 (Bradley
2006; Wiysonge 2007b; Wiysonge 2012; Wiysonge 2013). In the
previous search conducted in June 2006 (Bradley 2006;Wiysonge
2007b), we searched PubMed, Embase, Cochrane Database of
Systematic Reviews, and the York Database of Abstracts of Re-
views of Effectiveness for previous reviews and meta-analyses of
antihypertensive treatments that included beta-blockers. Reports
of relevant trials referred to in these reviews were obtained. We
then carried out an exhaustive search for eligible RCTs in MED-
LINE (for the period 1966 to June 2006) using the terms “adren-
ergic beta-antagonists” [MESH], “beta (blockers)” and exp “hy-
pertension” [MESH] combined with the optimally sensitive strat-
egy for identifying RCTs recommended by Cochrane (Higgins
2011); Embase (for the period 1980 to June 2006) using a search
strategy similar to that used for MEDLINE; and CENTRAL (the
Cochrane Library, 2016, Issue 2). Finally, experts in the field of
hypertension and drug companies manufacturing beta-blockers
were contacted for unpublished trials. After reaching consensus on
the search strategy for each electronic database, the information
specialist of the South African Cochrane Centre conducted the
respective electronic searches.
Searching other resources
The Cochrane Hypertension Information Specialist searched
the Hypertension Specialised Register segment (which includes
searches of MEDLINE for systematic reviews) to retrieve existing
systematic reviews relevant to this systematic review, so that we
could scan their reference lists for additional trials.
Where necessary, we contacted authors of key papers and abstracts
to request additional information about their trials.
We did not perform a separate search for adverse effects of inter-
ventions used for the treatment of hypertension. We considered
adverse effects described in included studies only.
We also screened the reference lists of 41 potentially eligible
studies and 25 relevant reviews and guidelines (Balamuthusamy
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2009; Bangalore 2007; Bangalore 2008; Bath 2014; Carlberg
2004; Chen 2010; Dahlöf 2007; ESH-ESC 2013; Gradman
2010; Howlett 2014; James 2014; Jennings 2013; Khan 2006;
Kuyper 2014; Larochelle 2014; NICE 2006; Poirier 2014; Pucci
2016; Ripley 2014; Sander 2011; Sciarretta 2011; Thomopoulos
2015; Wong 2014a; Wong 2014b; Wright 2009). In addition,
we searched the World Health Organization International Clin-
ical Trials Registry Platform (www.who.int/trialsearch) using the
terms (beta-blocker OR beta-blockers) AND hypertension on 06
July 2015.
Data collection and analysis
For the current update, two review authors (CSW and HB) in-
dependently examined the eligibility of all titles and abstracts of
studies identified by electronic or bibliographic scanning. The two
review authors then independently assessed the risk of bias within
included studies and extracted data. At each stage, the they re-
solved differences by discussion and consensus. If any discrepan-
cies had persisted, JV would have arbitrated.
We assessed the risk of bias by addressing seven specific domains,
as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The seven domains were
random sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment, in-
complete outcome data, selective outcome reporting, and other
bias’. For each included study, we described what the study au-
thors reported that they did for each domain and then made a
decision relating to the risk of bias for that domain; by assigning a
judgement of ’low risk’ of bias, ’high risk’ of bias, or ’unclear risk’
of bias.
The data extracted for each study were: methods, including means
of assigning participants to trial interventions, blinding of those
receiving and providing care and outcome assessors, losses to fol-
low-up and how they were handled, and length of trial follow-up;
participant characteristics, including gender, ethnicity and comor-
bid conditions; interventions, including type and dose of beta-
blocker and other medications used; outcome measures, including
morbidity and mortality endpoints, and adverse events.
We conducted quantitative analyses according to standard
Cochrane guidelines (Higgins 2011). We analysed trial partici-
pants in groups towhich theywere randomised, regardless ofwhich
or howmuch treatment they actually received, and expressed study
results as risk ratios (RR) with 95% confidence intervals (CI). We
assessed heterogeneity between studies by graphical inspection of
results and, more formally followed by, theChi2 test of homogene-
ity. In the absence of significant statistical heterogeneity between
studies (P > 0.1), we performed meta-analysis using a fixed-effect
method (Breslow 1980;Mantel 1959).When there was significant
heterogeneity between study results, we used the random-effects
method (DerSimonian 1986), and investigated the cause of het-
erogeneity by stratified analysis with reference to the characteris-
tics of the studies included in the meta-analysis. The study char-
acteristics considered in the subgroup analyses were age (less than
65 years versus 65 years and older), type of beta-blockade (cardios-
elective versus non-selective), control group (placebo versus no
treatment), and risk of bias (high versus low risk of bias). In addi-
tion, we used the I2 statistic to describe the percentage of between-
study variability in effect estimates (for each outcome) attributable
to true heterogeneity rather than chance (Higgins 2003).
Various related reviews differ from ours in their inclusion or exclu-
sion of various studies (Carlberg 2004; Dahlöf 2007; Khan 2006;
Lindhom 2005; Wright 2009). We conducted sensitivity analyses
to confirm that those different decisions did not lead to different
conclusions.
R E S U L T S
Description of studies
Figure 1 shows the search and selection of studies for this review, in
line with the statement of preferred reporting items for systematic
reviews and meta-analyses (Moher 2009).
Figure 1. PRISMA flow diagram showing the search and selection of studies.
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Results of the search
We obtained 4453 records from the search conducted in January
2015; including 696 duplicates. Of the remaining 3757 records,
1263 were new records. We screened these and found no poten-
tially eligible studies. The search conducted on 6 July 2015 found
450 studies in Clinicaltrials.gov and 283 records of 257 studies in
theWHOInternational Clinical Trials Registry Platform.None of
these ’ongoing’ studies was potentially eligible. Finally, the search
conducted in June 2016 yielded 2716 records, with 596 being du-
plicates. We screened the remaining 2120 records (of which 1551
were new records) and found no potentially eligible studies.
From the search conducted in June 2006, we identified 21 po-
tentially eligible RCTs (AASK 2002; ASCOT 2005; Berglund
1981; Coope 1986; ELSA 2002; HAPPHY 1987; INVEST
2003; IPPPSH 1985; LIFE 2002; MRC 1985; MRCOA 1992;
UKPDS-39-1998; VA COOP 1982; CAPP 1999; CONVINCE
1998; Dutch TIA 1993; MAPHY 1988; NORDIL 2000; STOP
1991; STOP-2 1999; TEST1995), fromwhichwe excluded eight.
Infive of the sixRCTs, participants in the ’beta-blocker’ groupwere
not randomly allocated to a beta-blocker at baseline but to conven-
tional therapy, which referred to either a beta-blocker or a diuretic
(CAPP 1999; CONVINCE 1998; NORDIL 2000; STOP 1991;
STOP-2 1999). None of the five RCTs reported data separately
for the participants taking beta-blockers and participants taking
diuretics. We excluded two studies because not all participants had
hypertension at baseline (Dutch TIA 1993; TEST 1995). We ex-
cluded the eighth RCT (MAPHY 1988), because it was a subset
of an included RCT (HAPPHY 1987).
The remaining 13 RCTs with 91,561 participants meet our inclu-
sion criteria (AASK 2002; ASCOT 2005; Berglund 1981; Coope
1986; ELSA 2002; HAPPHY 1987; INVEST 2003; IPPPSH
1985; LIFE 2002;MRC1985;MRCOA1992;UKPDS-39-1998;
VA COOP 1982), and we included them in the previous review
(Bradley 2006; Wiysonge 2007b).
The May 2011 search yielded 1566 records from the electronic
databases (after removingduplicates), whichwe screened and iden-
tified 19 potentially eligible studies (ACCORD 2010; ADaPT
2008; APSIS 2006; CAPRICORN 2001; CARDHIAC 2008;
CHHIPS 2009; CIBIS-II 1999; COMET 2003; COPE 2005;
COPERNICUS 2004; COSMOS 2010; Dietz 2008; GEMINI
2008; IMPACT-HF 2004; MERIT-HF 2002; Nilsson 2007;
REASON 2009; RESOLVD 2000; SENIORS 2005). Following
review of the full-text articles of the 19 studies, we found that none
of them met our inclusion criteria.
Finally, we obtained 508 abstracts from theDecember 2011 search;
with one potentially eligible study (Marazzi 2011). This study did
not met our inclusion criteria and was excluded.
Included studies
The 13 included RCTs compared a beta-blocker to a placebo or
no treatment (Coope 1986; IPPPSH 1985;MRC 1985;MRCOA
1992), a diuretic (Berglund 1981; HAPPHY 1987; MRC 1985;
MRCOA 1992; VA COOP 1982), a CCB (AASK 2002; ASCOT
2005; ELSA 2002; INVEST 2003), an ACE inhibitor (AASK
2002; UKPDS-39-1998), or an ARB (LIFE 2002).
Unlike two related reviews (Dahlöf 2007; Wright 2009), we did
not consider the UKPDS-39-1998 as a placebo-controlled trial
because participants in the ’less tight control group’ (which these
reviews consider as placebo) took antihypertensive treatment for
57% of total person-years.
Ten RCTs recruited participants of both sexes (AASK 2002;
ASCOT2005;Coope 1986; ELSA2002; INVEST2003; IPPPSH
1985; LIFE 2002; MRC 1985; MRCOA 1992; UKPDS-39-
1998). Six RCTs included participants up to the age of 65 years
(Berglund 1981; HAPPHY 1987; IPPPSH 1985; MRC 1985;
UKPDS-39-1998; VACOOP1982), and the rest included partic-
ipants aged 18 to 70 years (AASK 2002), 40 to 79 years (ASCOT
2005), 45 to 75 years (ELSA 2002), more than 50 years (INVEST
2003), 55 to 80 years (LIFE 2002), 60 to 79 years (Coope 1986),
and 65 to 74 years (MRCOA 1992).
All 13 studies were conducted in industrialised countries, mainly
Western Europe and North America. Nine RCTs provided infor-
mation on race or ethnicity: AASK 2002 (0% white), INVEST
2003 (44% white), VA COOP 1982 (48% white), UKPDS-39-
1998 (86% white), IPPPSH 1985 (92% white), LIFE 2002 (92%
white), ASCOT 2005 (95.0% white), ELSA 2002 (98.2% white),
and HAPPHY 1987 (more than 99% white).
We have described the 13 RCTs included in this review in detail
in the Characteristics of included studies table, and summarised
their main features below:
• AASK 2002. This RCT compared the effects of an ACE
inhibitor (ramipril), a CCB (amlodipine), and a beta-blocker
(metoprolol) on hypertensive renal disease progression in African
American people aged 18 to 70 years. Additional
antihypertensive agents were added sequentially to achieve blood
pressure goals. Cardiovascular events, cardiovascular mortality.
and all-cause mortality were reported. The trial followed 1094
participants for a mean duration of 4.1 years.
• ASCOT 2005. The participants were randomised to a CCB
(amlodipine) adding an ACE inhibitor (perindopril) as required
to reach blood pressure targets or a beta-blocker (atenolol)
adding a diuretic (bendroflumethiazide) as required. The
participants were men and women with hypertension aged 40 to
79 years. The main outcome measure was combined non-fatal
myocardial infarction and fatal CHD, and secondary endpoints
included all-cause mortality, cardiovascular mortality, and total
stroke. At the end of the trial, 78% of participants were taking at
least two antihypertensive medications and only 15% were
taking amlodipine and 9% were taking atenolol monotherapy.
The study enrolled 19,257 participants and followed them for a
median duration of 5.5 years.
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• Berglund 1981. This RCT evaluated the long-term effects
of a thiazide diuretic (bendroflumethiazide) compared to a beta-
blocker (propranolol) in men with hypertension aged 47 to 54
years. Hydralazine and other antihypertensive medications were
added to achieve blood pressure goals. The investigators reported
total mortality. At the end of the trial, 70% of participants taking
diuretic and 74% taking beta-blockers were on assigned
treatment and 40% of participants taking diuretic and 42%
taking beta-blocker were on monotherapy. The study enrolled
106 participants and the study lasted 10 years.
• Coope 1986. The trial was designed to determine whether
the treatment of hypertension using beta-blocker therapy
(atenolol) in a stepped-care approach compared to no treatment
reduced the incidence of stroke, CHD, cardiovascular death, or
all-cause mortality. Step one was monotherapy with atenolol,
step two added a thiazide diuretic (bendrofluazide), and steps
three and four added other antihypertensive agents. At the end of
the trial, 70% of participants in the beta-blocker group were
taking assigned treatment, 17% were taking atenolol alone, and
53% were taking atenolol plus bendrofluazide. The trial followed
up 884 participants aged 60 to 79 years for a mean duration of
4.4 years.
• ELSA 2002. The trial was designed to compare the effects
of a beta-blocker (atenolol) and a CCB (lacidipine) on the
change in mean maximum intima-media thickness and plaque
number in men and women with hypertension. The
investigators also reported data on fatal and non-fatal
cardiovascular events and total mortality. If satisfactory blood
pressure control was not achieved, trial medication could be
increased, and when necessary open-label hydrochlorothiazide
was added. At the end of the trial, 85% of participants in the
beta-blocker group and 78% in the CCB group were known to
be on assigned treatment. The participants on monotherapy at
the end of the trial were 43% in the beta-blocker group and 42%
in the CCB group. The trial followed up 2334 participants aged
45 to 75 years for a mean duration of 3.75 years.
• HAPPHY 1987. The trial was designed to compare the
effects of beta-blockers (mainly atenolol, 1599 participants or
metoprolol, 1631 participants) and thiazide diuretics
(bendroflumethiazide or hydrochlorothiazide) on the incidence
of non-fatal myocardial infarction, CHD mortality, and total
mortality in men with mild to moderate hypertension. Other
drugs were added to reduce blood pressure as necessary. At the
end of the trial, 86% of participants in the beta-blocker group
and 83% in the diuretic group were on assigned treatment. More
participants in the beta-blocker group (68%) than in the diuretic
group (62%) were on monotherapy. The trial followed up 6569
participants aged 40 to 64 years for a mean duration of 45.1
months.
• INVEST 2003. The trial was designed to compare the
effect of a CCB (verapamil sustained release, SR), and a beta-
blocker (atenolol) in hypertensive participants with documented
coronary artery disease, on all-cause and cardiovascular death,
and various non-fatal cardiovascular events. Other drugs, mainly
trandolapril (to the verapamil SR group) and
hydrochlorothiazide (to the atenolol group), were added to
achieve blood pressure control as required. At two years, 77.5%
of participants in the beta-blocker group and 81.5% in the CCB
group were on the assigned treatment (18.1% taking beta-
blocker and 17.4% taking CCB monotherapy). The trial
followed up 22,576 participants aged 50 years and older for a
mean duration of 2.7 years.
• IPPPSH 1985. The trial was designed to evaluate the effect
of antihypertensive therapy with a beta-blocker (oxprenolol) on
the incidence of cardiac events (myocardial infarction and
sudden death) and cerebrovascular accidents. Trial medication
could be increased or other non-beta-blocker antihypertensive
drugs added according to predefined recommendations, as
necessary, to reduce blood pressure. During the trial, 30% of
participants remained on beta-blocker monotherapy while 15%
remained on placebo only. The trial followed up 6357
participants aged 40 to 64 years for three to five years.
• LIFE 2002. The trial was designed to evaluate the effects of
an ARB (losartan) compared to a beta-blocker (atenolol) in
people with hypertension with documented left ventricular
hypertrophy on the combined incidence of cardiovascular
mortality and morbidity. Other drugs were added to reduce
blood pressure as necessary. At the end of the trial, 63% of
participants in the beta-blocker group and 67% in the ARB
group were on assigned treatment; 11% of participants were on
monotherapy in each group. The trial followed up 9193
participants aged 55 to 80 years for a mean duration of 4.8 years.
• MRC 1985. The trial was designed to determine whether
drug treatment of mild hypertension reduced the rates of fatal
and non-fatal stroke and of coronary events. Participants were
randomised to active treatment (propranolol or bendrofluazide)
or placebo. At the end of the study, the proportion of
participants on assigned treatment in the beta-blocker group was
59%, in the diuretic group was 62%, and placebo group was
56%. The trial followed up 17,354 participants aged 35 to 64
years for a mean duration of 4.9 years.
• MRCOA 1992. The trial was designed to establish whether
treatment of hypertension in older adults reduced the risk of
stroke, CHD, and death from all causes. Participants were
randomised to a beta-blocker (atenolol), a diuretic (amiloride
and hydrochlorothiazide), or placebo. Other drugs were added as
necessary. At five years, 52% of participants assigned to beta-
blockers required supplementary drugs compared to 38% in the
diuretic group. At the end of the study, 37% of participants in
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the beta-blocker group, 52% in the diuretic group, and 47% in
the placebo group were on the assigned treatment. The trial
followed up 4396 participants aged 65 to 74 years for 5.8 years.
• UKPDS-39-1998. The trial was designed to determine
whether tight control of blood pressure with either a beta-
blocker (atenolol) or an ACE inhibitor (captopril) prevents
macrovascular and microvascular complications in participants
with type 2 diabetes. Participants were randomised to study
drugs, with other drugs added as required. At the end of the trial,
65% of participants in the beta-blocker group and 78% in the
ACE inhibitor group were on assigned treatment. The trial
followed up 758 participants aged 25 to 65 years for 8.4 years.
• VA COOP 1982. This trial compared a beta-blocker
(propranolol) and a diuretic (hydrochlorothiazide) for the initial
treatment of hypertension in men aged 21 to 65 years. During
treatment, fewer participants receiving hydrochlorothiazide
required termination as compared with men receiving
propranolol. A total of 683 men were recruited. During the
initial 10 weeks (i.e. dose-finding period), the clinic staff titrated
the blinded drug upward until the target blood pressure was
reached. Participants were withdrawn from the study if, on any
follow-up visit, diastolic blood pressure was 120 mmHg or more.
The trial lasted one year.
Excluded studies
We excluded 28 potentially eligible studies because of the very
short duration of relevant interventions (CHHIPS 2009; Dietz
2008), a beta-blocker was not given as monotherapy or first-line
therapy (ACCORD 2010; CAPP 1999; CAPRICORN 2001;
CARDHIAC 2008; CIBIS-II 1999; CONVINCE 1998; COPE
2005; GEMINI 2008; Marazzi 2011; NORDIL 2000; STOP
1991; STOP-2 1999), the study was not an RCT (ADaPT 2008),
the study was a subset of an included RCT (MAPHY 1988),
the study has not reported data on mortality or hard cardio-
vascular endpoints (COSMOS 2010; Nilsson 2007), or not all
enrolled participants had hypertension (APSIS 2006; CIBIS-II
1999; CAPRICORN 2001; COMET 2003; COPERNICUS
2004; Dutch TIA 1993; IMPACT-HF 2004; MERIT-HF
2002; RESOLVD 2000; SENIORS 2005; TEST 1995).The tri-
als where not all enrolled participants had hypertension were
of beta-blockers in people with heart failure (CIBIS-II 1999;
COMET 2003; COPERNICUS 2004; IMPACT-HF 2004;
Marazzi 2011; MERIT-HF 2002; RESOLVD 2000; SENIORS
2005), angina pectoris (APSIS 2006), post-myocardial infarction
(CAPRICORN 2001), or transient ischaemic attack or stroke
(Dutch TIA 1993; TEST 1995).
We have described each of the 28 excluded studies in greater detail
in the Characteristics of excluded studies table.
Risk of bias in included studies
The risk of bias in included studies is summarised in Figure 2 and
Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Seven trials reported the method used to generate the randomi-
sation sequence adequately (ASCOT 2005; Coope 1986; ELSA
2002; INVEST 2003; IPPPSH 1985; LIFE 2002; UKPDS-39-
1998). It was unclear in the remaining six (AASK 2002; Berglund
1981; HAPPHY 1987; MRC 1985; MRCOA 1992; VA COOP
1982).
Five trials had adequate allocation concealment (ASCOT 2005;
Coope 1986; INVEST 2003; IPPPSH 1985; UKPDS-39-1998),
while in the remaining eight, the information provided was insuf-
ficient to assess this aspect of risk of bias (AASK 2002; Berglund
1981; ELSA 2002; HAPPHY 1987; LIFE 2002; MRC 1985;
MRCOA 1992; VA COOP 1982).
Blinding
Outcome assessors were blinded in 11 studies (AASK 2002;
ASCOT 2005; Coope 1986; ELSA 2002; HAPPHY 1987;
INVEST2003; IPPPSH 1985; LIFE 2002;MRC 1985;MRCOA
1992; VACOOP1982), and two trials were completely unblinded
(Berglund 1981; UKPDS-39-1998). However, in the Berglund
1981 study, the outcome assessed (i.e. death) is unlikely to be in-
fluenced by lack of blinding.
Participants were also blinded in seven trials (AASK 2002; ELSA
2002; IPPPSH 1985; LIFE 2002; MRC 1985; MRCOA 1992;
VA COOP 1982), but healthcare workers were only blinded in
five trials (AASK 2002; ELSA 2002; IPPPSH 1985; LIFE 2002;
VA COOP 1982) .
Incomplete outcome data
Loss to follow-up was negligible in AASK 2002 (0%), ASCOT
2005 (0.3%), IPPPSH 1985 (0.6%), HAPPHY 1987 (1%), LIFE
2002 (2%), INVEST 2003 (2.5%), ELSA 2002 (4%), UKPDS-
39-1998 (4%), Berglund 1981 (7%), and VA COOP 1982 (8%),
but high in MRC 1985 (19%) and MRCOA 1992 (25%) trials.
Coope 1986 did not report loss to follow-up.
The following trials stated the proportions of participants taking
assigned beta-blocker treatment at the end of the trial: HAPPHY
1987 (86%), ELSA 2002 (85%), Berglund 1981 (74%), Coope
1986 (70%), UKPDS-39-1998 (65%), LIFE 2002 (63%), MRC
1985 (59%), VACOOP 1982 (39%), MRCOA 1992 (37%), and
IPPPSH 1985 (30%).
Selective reporting
Ten studies reported outcomes as stated in the respective study
protocols (AASK 2002; ASCOT 2005; ELSA 2002; HAPPHY
1987; INVEST 2003; IPPPSH 1985; LIFE 2002; MRC 1985;
MRCOA 1992; UKPDS-39-1998). We did not have access to the
study protocols of the remaining studies (Berglund 1981; Coope
1986; VA COOP 1982).
Other potential sources of bias
All the studies added other antihypertensive drugs to the first-line
treatment to help achieve the blood pressure goals. The observed
effects may equally have resulted from the additional drugs used.
In addition, two studies were stopped early for data-dependent
reasons (AASK 2002; ASCOT 2005).
The high risk of bias in most of the included studies limits our
confidence in the effect estimates for beta-blockers as first-line
therapy for hypertension (Balshem 2011; Guyatt 2011), as shown
in the ’Summary of findings’ tables (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4).
Effects of interventions
See: Summary of findings for the main comparison Beta-
blockers versus placebo as first-line therapy for hypertension;
Summary of findings 2 Beta-blockers compared to diuretics
as first-line therapy for hypertension; Summary of findings 3
Beta-blockers compared to calcium-channel blockers as first-line
therapy for hypertension; Summary of findings 4 Beta-blockers
compared to renin-angiotensin system inhibitors as first-line
therapy for hypertension
Due to the small number of participants in trials with ACE in-
hibitors (2 trials with 1635 participants (AASK 2002; UKPDS-
39-1998)) and ARBs (1 trial with 9193 participants (LIFE 2002)),
we combined data for the two classes of RAS inhibitors. We ex-
cluded the trial that compared the effects of atenolol and aliskiren,
the first DRI to be approved for the treatment of hypertension
(Dietz 2008), because of the very short duration (12 weeks) of
relevant interventions.
Mortality
The effect of beta-blocker therapy on total mortality was not sig-
nificantly different from that of placebo (4 trials, 23,613 partici-
pants: RR 0.99, 95% CI 0.88 to 1.11; I2 = 0%; moderate certainty
evidence).
Apart from the four studies included in our placebo comparison,
previous related reviews included four other studies (Dutch TIA
1993; STOP 1991; TEST 1995; UKPDS-39-1998). When we
added these studies in a sensitivity analysis, there was still no evi-
dence of a significant effect of beta-blockers on mortality (8 trials,
28,181 participants: RR 0.93, 95% CI 0.85 to 1.02, I2 = 39%).
In addition, total mortality was not significantly different between
beta-blockers and diuretics (5 trials, 18,241 participants: RR 1.04,
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95% CI 0.91 to 1.19, I2 = 0%; moderate certainty evidence), and
beta-blockers andRAS inhibitors (3 trials, 10,828 participants: RR
1.10, 95% CI 0.98 to 1.24, I2 = 54%; moderate certainty evidence).
Total mortality was significantly higher for beta-blockers com-
pared to CCBs (4 trials, 44,825 participants: RR 1.07, 95% CI
1.00 to 1.14, I2 = 2%; moderate certainty evidence) corresponding
to an absolute risk increase (ARI) of 0.5% and number of partici-
pants needed to treat for an additional harmful outcome (NNTH)
with a beta-blocker rather than a CCB treated for five years of 200.
Total stroke
Participants treated with a beta-blocker had a significantly lower
risk of developing a stroke than participants taking placebo (4
trials, 23,613 participants: RR 0.80, 95% CI 0.66 to 0.96, I2 =
0%; low certainty evidence). A sensitivity analysis adding the four
studies included in related reviews yielded similar results (8 trials,
28,181 participants: RR 0.79, 95% CI 0.70 to 0.90, I2 = 31%).
Expressed as absolute risk reduction (ARR), beta-blockers reduced
the risk of stroke by 0.5% (compared to placebo). The correspond-
ing number of participants needed to treat for an additional ben-
eficial outcome (NNTB) with a beta-blocker for approximately
five years to prevent one stroke was 200.
We found no statistically significant difference in stroke events
between participants treated with a beta-blocker and participants
treated with a diuretic (4 trials, 18,135 participants: RR (ran-
dom effects) 1.17, 95% CI 0.65 to 2.09, I2 = 73%; moderate cer-
tainty evidence). However, participants treated with a beta-blocker
(atenolol) had more stroke events than participants treated with a
CCB (3 trials, 44,167 participants: RR 1.24, 95%CI 1.11 to 1.40,
I2 = 0%; ARI = 0.6%, NNTH 180; moderate certainty evidence)
or an RAS inhibitor (2 trials, 9951 participants: RR 1.30, 95%
CI 1.11 to 1.53, I2 = 29%; ARI = 1.5%, NNTH 65; moderate
certainty evidence).
The heterogeneity among trials comparing beta-blockers to di-
uretics may be related to the type of beta-blockade (I2 = 73%, P
= 0.01). There was an increase in the risk of stroke with the non-
selective beta-blocker, propranolol, in the MRC 1985 trial (RR
2.28, 95% CI 1.31 to 3.95) with an ARI of 0.5% and NNTH
with a beta-blocker for approximately five years of 200; but no dif-
ference with the cardio-selective beta-blockers, atenolol or meto-
prolol (RR 1.00, 95% CI 0.74 to 1.33, I2 = 60).
Total coronary heart disease
The effect of beta-blocker therapy on CHD was not significantly
different from that of a placebo (4 trials, 23,613 participants: RR
0.93, 95% CI 0.81 to 1.07, I2 = 0%; moderate certainty evidence).
A sensitivity analysis adding the four studies included in related
reviews yielded similar results (8 trials, 28,181 participants: RR
0.91, 95% CI 0.81 to 1.02, I2 = 0%).
The beta-blocker effect was similar to that of a diuretic (4 trials,
18,135 participants: RR (random effects) 1.12, 95% CI 0.82 to
1.54, I2 = 66%; low certainty evidence), a CCB (3 trials, 44,167
participants: RR 1.05, 95% CI 0.96 to 1.15, I2 = 32%; moderate
certainty evidence), or a RAS inhibitor (2 trials, 9951 participants:
RR 0.90, 95% CI 0.76 to 1.06, I2 = 42%; low certainty evidence).
There was significant statistical heterogeneity between trials com-
paring beta-blockers to diuretics (I2 = 66%, P = 0.03), which may
be explained by differences in age. The pooled RR in the trials
whose participants were less than 65 years of age was 0.97 (95%
CI 0.81 to 1.17, I2 = 5%, P = 0.35), while in the single trial in-
volving participants aged 65 years and older atenolol was associ-
ated with an increased CHD incidence (RR 1.63, 95% CI 1.15
to 2.32) (MRCOA 1992). The difference between the subgroups
was statistically significant (test for subgroup differences: Chi2 =
6.70, degrees of freedom (df ) = 1, P = 0.01, I2 = 85.1%).
Total cardiovascular disease
Compared toparticipants takingplacebo, participants takingbeta-
blockers had a significantly reduced risk of having a cardiovascular
event (4 trials, 23,613 participants: RR 0.88, 95% CI 0.79 to
0.97, I2 = 21%; ARR 0.7%, NNTB 140 for 5 years; low certainty
evidence). A sensitivity analysis adding studies included in related
reviews yielded similar results.
The effect of beta-blockers on total cardiovascular events was not
significantly different from that of diuretics (4 trials, 18,135 par-
ticipants: RR 1.13, 95% CI 0.99 to 1.28, I2 = 45%; moderate cer-
tainty evidence) and RAS inhibitors (3 trials, 10,828 participants:
RR (random effects) 1.00, 95%CI 0.72 to 1.38, I2 = 74%; low cer-
tainty evidence). Beta-blockers increased total cardiovascular dis-
ease as compared to CCBs (2 trials, 19,915 participants: RR 1.18,
95% CI 1.08 to 1.29, I2 = 0%; ARI = 1.3%, NNTH 80; moderate
certainty evidence).
The significant heterogeneity of effect on total cardiovascular dis-
ease between beta-blockers and RAS inhibitors (I2 = 74%, P =
0.02) was explained by the effect of beta-blockers being similar to
that of ACE inhibitors (2 trials, 635 participants: RR 0.82, 95%
CI 0.64 to 1.05, I2 = 0%) but worse than that of an ARB (1 trial,
9193 participants: RR 1.16, 95% CI 1.04 to 1.30) with an ARI
of 1.8% and NNTH of 56.
Adverse events leading to discontinuation of
allocated treatment
We analysed data on the rate of withdrawal from randomly as-
signed treatment due to any adverse events, and also report on the
frequency of specific adverse events including depression, fatigue,
and sexual dysfunction.
Trial participants on a beta-blocker were no more likely than par-
ticipants receiving a placebo to discontinue treatment due to ad-
verse events (3 trials, 22,729 participants: RR (random effects)
3.38, 95% CI 0.82 to 13.95; low certainty evidence). However,
there was significant heterogeneity of effect between the trials (I
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2 = 100%, P < 0.00001); with no difference in the likelihood of
discontinuing treatment with oxprenolol (1 trial, 6357 partici-
pants: RR 0.95, 95% CI 0.87 to 1.04) and an increased likelihood
with propranolol or atenolol (2 trials, 16,372; RR (random effects)
6.35, 95% CI 3.94 to 10.22, I2 = 91%). A sensitivity analysis
adding studies included in related reviews also revealed significant
heterogeneity of effect (I2 = 99%, P < 0.00001).
Participants taking a beta-blocker were more likely to discontinue
treatment due to adverse events than participants taking a RAS
inhibitor (2 trials, 9951 participants: RR 1.41, 95% CI 1.29 to
1.54, I2 = 12%; ARI 5.5%, NNTH 18; low certainty evidence),
but there was no significant difference with a diuretic (3 trials,
11,566 participants: RR (random effects) 1.69, 95% CI 0.95 to
3.00, I2 = 95%; low certainty evidence) or a CCB (2 trials, 21,591
participants: RR (random effects) 1.20, 95% CI 0.71 to 2.04, I2
= 93%; low certainty evidence).
There was no significant difference in the incidence of depressive
symptoms between beta-blockers and placebo (2 trials, 7082 par-
ticipants: RR (random effects) 1.03, 95% CI 0.65 to 1.63, I2 =
83.0) or RAS inhibitors (1 trial, 758 participants: RR 1.12, 95%
CI 0.07 to 17.80).
Beta-blockers did not increase the risk of fatigue compared to
placebo or no treatment (2 trials, 13,782 participants: RR (ran-
dom effects) 4.35, 95%CI 0.17 to 108.74, I2 = 99.0%). However,
trial participants taking a beta-blocker were more likely to develop
fatigue than participants taking a diuretic (1 trial, 8700 partici-
pants: RR 2.48, 95% CI 1.73 to 3.54), a CCB (1 trial, 19,257
participants: RR 1.99, 95% CI 1.84 to 2.16), or a RAS inhibitor
(2 trials, 9951 participants: RR 1.17, 95% CI 1.06 to 1.28, I2 =
0%).
The risk of sexual dysfunction was not different between beta-
blockers and placebo (2 trials, 19,414 participants: RR (random
effects) 1.95, 95% CI 0.33 to 11.59, I2 = 97.5%). However, beta-
blockers decreased the risk of sexual dysfunction when compared
to diuretics (1 trial, 8700 participants: RR 0.50, 95% CI 0.36
to 0.70); but increased the risk relative to CCBs (1 trial, 19,257
participants: RR 1.27, 95% CI 1.14 to 1.42) and RAS inhibitors
(2 trials, 9951 participants: RR 1.34, 95% CI 1.10 to 1.63, I2 =
56.2%).
Degree of reduction in systolic and diastolic blood
pressure achieved by beta-blocker therapy in relation
to each comparator treatment
Compared to placebo, first-line beta-blockers plus supplementary
antihypertensive drugs reduced systolic blood pressure by about
11 mmHg and diastolic blood pressures by about 6 mmHg (Table
2). However, compared to diuretics, CCBs, or RAS inhibitors, the
mean systolic and diastolic blood pressures at the end of the trials
were 0 to 2 mmHg higher in the beta-blocker group (Table 2).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Beta-blockers compared to diuretics as first- line therapy for hypertension
Participants: people with hypertension
Settings: high-income countries, mainly Western Europe and North America
Intervention: beta-blockers
Comparison: diuret ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95%CI)
No of participants
(studies)
Certainty of the evidence
(GRADE)
Assumed risk Corresponding risk
Diuretics Beta-blockers
Total mortality 41 per 1000 43 per 1000
(37 to 49)
RR 1.04
(0.91 to 1.19)
18241
(5 studies)
⊕⊕⊕©
Moderate1
Total cardiovascular dis-
ease
45 per 1000 51 per 1000
(45 to 58)
RR 1.13
(0.99 to 1.28)
18135
(4 studies)
⊕⊕⊕©
Moderate1
Total stroke 12 per 1000 14 per 1000
(8 to 25)
RR 1.17
(0.65 to 2.09)
18135
(4 studies)
⊕⊕©©
Low1,2
Total coronary heart dis-
ease
33 per 1000 37 per 1000
(27 to 50)
RR 1.12
(0.82 to 1.54)
18135
(4 studies)
⊕⊕©©
Low1,2
Withdrawal due to adverse
effect
109 per 1000 184 per 1000
(104 to 327)
RR 1.69
(0.95 to 3.00)
11566
(3 studies)
⊕⊕©©
Low1,2
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
1 The two studies that contribute to the most weight of the pooled RR have high risk of bias (especially incomplete outcome
report ing due to attrit ion bias): downgraded by 1 point.
2 Inconsistent results across studies (I2 = 73% for stroke, 66% for coronary heart disease, and 95% for adverse ef fects):
downgraded by 1 point.
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Beta-blockers compared to calcium-channel blockers as first- line therapy for hypertension
Participants: people with hypertension
Settings: high-income countries, mainly Western Europe and North America
Intervention: beta-blockers
Comparison: calcium-channel blockers
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Certainty of the evidence
(GRADE)
Assumed risk Corresponding risk
Calcium-channel blockers Beta-blockers
Total mortality 73 per 1000 78 per 1000
(73 to 83)
RR 1.07
(1.0 to 1.14)
44825
(4 studies)
⊕⊕⊕©
Moderate1
Total cardiovascular dis-
ease
81 per 1000 96 per 1000
(87 to 104)
RR 1.18
(1.08 to 1.29)
19915
(2 studies)
⊕⊕⊕©
Moderate2
Total stroke 23 per 1000 29 per 1000
(26 to 32)
RR 1.24
(1.11 to 1.4)
44167
(3 studies)
⊕⊕⊕©
Moderate3
Total coronary heart dis-
ease
39 per 1000 41 per 1000
(37 to 45)
RR 1.05
(0.96 to 1.15)
44167
(3 studies)
⊕⊕⊕©
Moderate3
Withdrawal due to adverse
effect
33 per 1000 40 per 1000
(23 to 67)
RR 1.20
(0.71 to 2.04)
21591
(2 studies)
⊕⊕©©
Low2,4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
1 The RR is too close to 1 and could easily include 1 if more trials are added: downgraded by 1 point.
2 Only 2 hypertension trials comparing beta-blockers to calcium-channel blockers have reported data on this outcome:
downgraded by 1 point.
3 Only 3 hypertension trials comparing beta-blockers to calcium-channel blockers have reported data on this outcome:
downgraded by 1 point.
4 Inconsistent results across studies (I2 = 93%): downgraded by 1 point.
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Beta-blockers compared to renin-angiotensin system inhibitors as first- line therapy for hypertension
Participants: people with hypertension
Settings: high-income countries, mainly Western Europe and North America
Intervention: beta-blockers
Comparison: renin-angiotensin system inhibitors
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95%CI)
No of participants
(studies)
Certainty of the evidence
(GRADE)
Assumed risk Corresponding risk
Renin-angiotensin system
inhibitors
Beta-blockers
Total mortality 84 per 1000 92 per 1000
(82 to 104)
RR 1.10
(0.98 to 1.24)
10828
(3 studies)
⊕⊕⊕©
Moderate1
Total cardiovascular dis-
ease
115 per 1000 115 per 1000
(83 to 159)
RR 1.0
(0.72 to 1.38)
10828
(3 studies)
⊕⊕©©
Low1,2
Total stroke 51 per 1000 66 per 1000
(56 to 77)
RR 1.30
(1.11 to 1.53)
9951
(2 studies)
⊕⊕⊕©
Moderate3
Total coronary heart dis-
ease
54 per 1000 49 per 1000
(41 to 57)
RR 0.90
(0.76 to 1.06)
9951
(2 studies)
⊕⊕©©
Low3,4
Withdrawal due to adverse
effect
137 per 1000 194 per 1000
(177 to 211)
RR 1.41
(1.29 to 1.54)
9951
(2 studies)
⊕⊕⊕©
Moderate3
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
1 Only 3 hypertension trials comparing beta-blockers to RAS inhibitors have reported data on this outcome: downgraded by 1
point.
2 Inconsistent results across studies (I2 = 74%): downgraded by 1.
3 Only 2 hypertension trials comparing beta-blockers to RAS inhibitors have reported data on this outcome: downgraded by 1
point.
4 Imprecise results, as the ef fect ranges f rom a clinically important benef it to a small increase in harm: downgraded by 1
point.
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D I S C U S S I O N
Summary of main results
We included 13 eligible RCTs, which compared beta-blockers to
placebo, diuretics, CCBs, and RAS inhibitors. These RCTs gen-
erally had a high risk of bias resulting from limitations in study
design, conduct, and data analysis.
We found little or no difference in all-cause mortality between
beta-blockers and placebo, diuretics or RAS inhibitors, but all-
cause mortality was higher for beta-blockers compared to CCBs.
The evidence on mortality was of moderate-certainty for all com-
parisons. Total cardiovascular disease was lower for beta-blockers
compared to placebo, which is a reflection of the significant de-
crease in stroke, since there was little or no difference in CHD be-
tween beta-blockers and placebo. There were no significant differ-
ences between beta-blockers and placebo in adverse events leading
to withdrawal from assigned treatment (low-certainty evidence).
The effect of beta-blockers on cardiovascular disease was worse
than that of CCBs (moderate-certainty evidence), but was not
different from that of diuretics (moderate-certainty evidence) or
RAS inhibitors (low-certainty evidence). In addition, there was an
increase in stroke with beta-blockers compared to CCBs (mod-
erate-certainty evidence) and RAS inhibitors (moderate-certainty
evidence). However, there was little or no difference in CHD be-
tween beta-blockers and diuretics (low-certainty evidence), CCBs
(moderate-certainty evidence), or RAS inhibitors (low-certainty
evidence). Participants taking beta-blockers were more likely to
discontinue treatment due to adverse events than participants tak-
ing RAS inhibitors (moderate-certainty evidence), but there was
no significant difference with diuretics (low-certainty evidence) or
CCBs (low certainty evidence).
We demonstrated a high degree of homogeneity of effect for the
comparisons of beta-blockers versus CCBs for all-cause mortality
(I2 = 2%), stroke (I2 = 0%), and total cardiovascular events (I2
= 0%) but with less homogeneity for CHD (I2 = 32%). For the
comparison of beta-blockers versus RAS inhibitors, the I2 values
for stroke and withdrawal rates also demonstrate a high degree of
consistency across the studies making our conclusions more secure
(Higgins 2003; Higgins 2011). For the comparison with diuretics,
there were no statistically significant differences in any morbidity
or mortality outcome.
Overall completeness and applicability of
evidence
Though beta-blockers are a heterogeneous group of pharmacolog-
ical agents, differing in beta-adrenergic receptor selectivity, intrin-
sic sympathomimetic activity, and vasodilatory capabilities (Kamp
2010; Pedersen 2007; Polónia 2010), we found no outcome tri-
als with head-to-head comparisons between beta-blockers for the
treatment of hypertension (Poirier 2014). Of the 40,245 partic-
ipants using beta-blockers in this review, atenolol was used by
30,150 participants (75%). Due to the paucity of data using beta-
blockers other than atenolol, it is not possible to say whether the
(lack of ) effectiveness and (in)tolerability of beta-blockers seen in
this review is a property of atenolol or is a class effect of beta-block-
ers. From this review, we cannot support the claim by Lindhom
and colleagues that cardioselective beta-blockers may be inferior
to non-selective beta-blockers in the treatment of hypertension
(Carlberg 2004).
A limitation of both previous reviews and ours is the absence of
trials assessing the effects of the new vasodilating beta-blockers
(e.g. carvedilol, bucindolol, and nebivolol) on mortality and hard
cardiovascular outcomes. Possible mechanisms to explain the poor
ability of beta-blockers to reduce stroke include a propensity to
cause diabetes (Opie 2004), a failure to decrease central aortic
pressure as much as brachial pressure, and others. Diabetes likely
requires years to develop cardiovascular complications (Verdecchia
2004), so we favour the mechanism involving lesser reduction of
central aortic pressure by beta-blockers. Vasodilating beta-blockers
(Broeders 2000; Kalinowski 2003; Pucci 2016) have been shown
to reduce central pressures better than conventional beta-block-
ers (Kamp 2010; Polónia 2010); most probably because vasodi-
latation favourably alters the pattern of the pressure wave reflect-
ing back from the periphery, thereby lowering the central pres-
sure. Nonetheless, carvedilol and nebivolol also cause bradycardia,
which is thought to be the principal mechanism whereby atenolol
with or without thiazide may be less able to lower the central
pressure than amlodipine with or without perindopril (Williams
2006). At any rate, high-quality outcome studies are required to
show that hard cardiovascular endpoints such as stroke and CHD
are significantly reduced by beta-blockers not studied in this re-
view.
Information reported in the trials considered in this review was
insufficient to explore the effect of race or ethnicity, as most trial
participants were white (Park 2007). However, the finding that
beta-blockers are less effective than diuretics in older people, is
most likely to be applicable to older black people as well (Materson
1993).
Quality of the evidence
The certainty of the evidence on the effects of beta-blockers was
generallymoderate to low (Balshem 2011). In theGRADE system,
RCTs without important limitations constitute high-certainty ev-
idence. However, the system considers five factors that can lower
the certainty of the evidence: study limitations, heterogeneity, indi-
rectness, imprecision, and publication bias. Overall, the GRADE
system classifies research evidence into high-, moderate-, low-, or
very low-certainty. Low-certainty evidence implies that the “true
effect is likely to be different from the estimate of effect” found in
the review.
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Our major concern with the evidence related to inherent short-
comings in the included primary studies. The emphasis was often
on the results with the first drug used, whereas most studies used
stepped-up therapy to help achieve the blood pressure goals. Thus
poorer outcomes with first-line beta-blockers may equally have re-
sulted from the use of other drugs; explaining why other authors
restricted their systematic reviews of beta-blocker therapy to tri-
als where confounding supplementary drug classes were adminis-
tered to less than half of participants (Wright 1999; Wright 2000;
Wright 2009). Although we were less restrictive than Wright and
colleagues (Wright 1999; Wright 2000), we included only trials in
which all the participants in one group received a beta-blocker at
baseline, whether or not other antihypertensive drug classes were
later added to achieve blood pressure targets. This requirement
was in contrast to other systematic reviews (Carlberg 2004;Dahlöf
2007; Khan 2006; Lindhom 2005). The dropout rates were high
in two of the studies of diuretics, potentially introducing attrition
bias (MRC 1985; MRCOA 1992).
It may be that only people with complicated hypertension or ad-
vanced disease are included in most studies, thereby ignoring the
possible differing benefits of different antihypertensive medica-
tions on different organs and on different stages of disease devel-
opment (Zanchetti 2005). A further problem is that in the two
groups of the studies we analysed, and especially in the case of
the comparison with diuretics, there were discrepancies between
the achieved blood pressure levels (Table 2), and even small blood
pressure differencesmay be linked to significant differences in out-
comes (Collins 1990; Staessen 2003).However, there were no con-
sistent differences in the blood pressure reduction between beta-
blockers and the other agents used to explain the outcome differ-
ences we found (Table 2). Yet another limitation is that (due to
the scarcity of relevant trials) we combined the potentially differ-
ent classes of RAS inhibitors (i.e. ACE inhibitors (captopril and
lisinopril) and ARB (losartan). However, we believe that the sim-
ilarities between these agents as antihypertensive drugs outweigh
any potential differences.
Potential biases in the review process
We minimised potential biases in the review process by adhering
to the Cochrane guidelines (Higgins 2011).We conducted a com-
prehensive search for eligible studies, without limiting the search
to a specific language. Two review authors independently assessed
study eligibility, extracted data, and assessed the risk of bias in each
included study.
Agreements and disagreements with other
studies or reviews
We showed that beta-blockers are inferior to various CCBs for all-
causemortality, stroke, and total cardiovascular events, and toRAS
inhibition for stroke. By comparing beta-blockers with all other
therapies, Lindholm and colleagues were only able to show an
inferiority of beta-blockade on stroke reduction (Carlberg 2004;
Lindhom 2005). In a similar meta-analysis, Khan and McAlister
found beta-blockers to be inferior to all other therapies in effects
on a composite outcome of major cardiovascular events (stroke,
myocardial infarction, and death) and stroke for older people with
hypertension but found no difference in effects for younger people
(Khan 2006). The claim by Khan 2006 that the defects of beta-
blockade are limited to older people relies heavily on the Medical
Research Council trial in older people with hypertension in which
the beta-blocker was atenolol and where the dropout rate was 25%
(MRCOA 1992). In addition, Khan 2006 classified trials which
enrolled participants as young as 40 (ASCOT 2005), 45 (ELSA
2002), and 50 (INVEST 2003) years as trials of older people with
hypertension. At present, there are insufficient data tomake a valid
comparison of beta-blocker effects on younger versus older people,
although this is an important hypothesis.
We used the I2 statistic to evaluate the consistency in study results
(Higgins 2003; Higgins 2011). In our meta-analyses, heterogene-
itywas very low for the outcomes of beta-blockers versus placebo or
no treatment.We found amodest 20% relative reduction in stroke
by beta-blockers compared to placebo with six studies, which is
similar to the relative reduction reported by Lindholm and col-
leagues using seven studies (Lindhom 2005). With their wider
inclusion criteria, Lindholm and colleagues included three stud-
ies not considered by us (Dutch TIA 1993; STOP 1991; TEST
1995), which resulted in significant heterogeneity of effect in their
findings. By contrast, there was excellent homogeneity of effect
with the four studies included in our comparison of beta-blockers
to placebo as shown by an I2 value of 0% (Coope 1986; IPPPSH
1985; MRC 1985; MRCOA 1992). Thus, we were able to give
additional validation to one of the crucial findings of Lindholm
and colleagues (Lindhom 2005), namely that stroke reduction by
beta-blockade is suboptimal.
Two other reviews also differed from ours in their inclusion or ex-
clusion of various studies (Dahlöf 2007; Wright 2009). Both con-
sidered the UKPDS-39-1998 as a placebo-controlled trial and ex-
cluded IPPPSH 1985. In addition, Wright 2009 excluded Coope
1986 because of high use of diuretics in the beta-blocker group
while Dahlöf 2007 included STOP 1991 because more than 85%
of participants on active treatment received beta-blocker as first-
line or second-line therapy. Both reviews considered the “less tight
control group” in UKPDS-39-1998 as “placebo” because the tar-
get for blood pressure reduction in this group was not as low as
in the beta-blocker group. However, participants in this control
group took antihypertensive treatment for 57% of their total per-
son-years in the UKPDS-39-1998 trial.
We combined trials of low-dose and high-dose thiazide diuretics
because of the paucity of trials comparing beta-blockers to diuretics
(Berglund1981;HAPPHY1987;MRC1985;MRCOA1992;VA
COOP 1982). This may be the reason for the lack of a statistical
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difference between beta-blockers and diuretics in our review, since
Wright and Musini have shown that first-line low-dose thiazides
reduce stroke, CHD, andmortality outcomeswhile first-line high-
dose thiazides have no significant effects on mortality and CHD
(Wright 2009).
We conducted sensitivity analyses and found our results to be
consistent with those of the related reviews, despite differences in
inclusion and exclusion criteria (Effects of interventions). Overall,
despite a variation in the studies included in other beta-blocker
reviews arising from different interpretations of inclusion criteria,
all the reviews arrived at similar conclusions that the available
evidence does not support the use of beta-blockers as first-line
drugs in the treatment of hypertension.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
First-line beta-blockers in peoplewith hypertension lead tomodest
reductions in stroke and have no significant effects on total mor-
tality and coronary heart disease. In addition, beta-blockers are in-
ferior to calcium-channel blockers and renin-angiotensin system
inhibitors for various important outcomes. Most of this evidence
is considered to be of lowquality according to theGRADE system,
implying that further research is likely to change our confidence in
the estimate of these effects. However, the evidence comes mainly
from trials that used atenolol. Our findings extend the results of
previous meta-analyses suggesting that beta-blockers are inferior
first-line choices when compared to diuretics, renin-angiotensin
system inhibitors, and calcium-channel blockers.
Implications for research
More randomised controlled trials studying the use of beta-block-
ers for elevated blood pressure are required. Such hypertension
trials must measure clearly defined morbidity and mortality end-
points, including coronary heart disease, heart failure, and stroke.
These trials should be used to define differences between beta-
blockers and other classes of antihypertensive drugs and between
the different subclasses of beta-blockers. In addition, the possible
differential effect of beta-blockers on younger and older people
needs to be assessed in future hypertension trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AASK 2002
Methods Multicentre study
Randomisation: described as randomised controlled trial, but method of allocating par-
ticipants to treatment was not described
Blinding: participants, providers, and outcome assessors blinded
Loss to follow-up: 0%
Mean duration of follow-up: 4.1 years
Analyses: by intention-to-treat
Participants Geographic location: USA
Study setting: hospital
Number of participants: 1094 (61.2% men)
Age range: 18 to 70 years (mean: 54 years)
Entry criteria: DBP ≥ 95 mmHg (mean BP 150/96 mmHg) and glomerular filtration
rate 20 mL/minute/1.73 m2 to 65 mL/minute/1.73 m2 and no other identified causes
of renal insufficiency
Race: all African Americans
Exclusion criteria: DBP < 95mmHg, known history of diabetes mellitus, urinary protein
to creatinine ratio > 2.5, accelerated or malignant hypertension within 6 months, sec-
ondary hypertension, non-BP-related causes of kidney disease, serious systemic disease,
clinical CHF, or specific (contra)indication for a study drug or procedure
Interventions Beta-blocker group:
Metoprolol 50 mg/day to 200 mg/day
ACE inhibitor group:
Ramipril 2.5 mg/day to 10 mg/day
Calcium-channel blocker group:
Amlodipine 5 mg/day to 10 mg/day
If the BP goal could not be achieved by the randomly allocated drug, additional open-
labelled antihypertensive drugs were added sequentially
Outcomes Cardiovascular events
Cardiovascular mortality
All-cause mortality
Notes A formal stopping rule was constructed based on the primary renal function analysis
with separate O’Brien-Fleming boundaries for the chronic and total mean slopes for
each of the 3 primary treatment group comparisons. The stopping rule stipulated that
a treatment group should be discontinued at 1 of the study’s annual interim analyses if
the stopping boundaries indicating faster progression were crossed in the same direction
for both the chronic and total mean slopes
Risk of bias
Bias Authors’ judgement Support for judgement
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AASK 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Described as “randomly allocated”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0%
Participants withdrawing from the study
were accounted for in an intention-to-treat
analysis
Selective reporting (reporting bias) Low risk Reported all outcomes as stated in protocol
Other bias Unclear risk Amlodipine group terminated early at rec-
ommendation of Data and Safety Moni-
toring Board, according to predetermined
stopping rules
Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
ASCOT 2005
Methods Multicentre study
Randomisation: computer-generated, using separate lists for each co-ordinating centre.
Participating physicians called the co-ordinating centre to obtain the treatment allocation
for each participant. Open treatment and blinded endpoint evaluation (PROBE) design
Loss to follow-up: 0.3% withdrew consent and 0.3% lost to follow-up
Median duration of follow-up: 5.5 years
Analyses: by intension-to-treat
Participants Geographic location: UK, Ireland, Denmark, Finland, Iceland, Norway, and Sweden
Study setting: hospital and primary care
Number of participants: 19,257 (76.6% men)
Age range: 40 to 79 years (mean: 63 years)
Entry criteria: sitting SBP ≥ 160 with or without DBP 100 mmHg (for people with
untreated hypertension) OR SBP≥ 140 with or without DBP ≥ 90 mmHg (for people
taking antihypertensive treatment), and 3 CHD risk factors
Race: 95% white
Exclusion criteria: previous MI, current angina, cerebrovascular event in previous 3
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ASCOT 2005 (Continued)
months, fasting triglycerides > 4.5 mmol/L, heart failure, uncontrolled arrhythmias, or
any clinically important haematological or biochemical abnormality on routine screening
Comorbid conditions: current smoking (33%), LVH (22%), type 2 diabetes (27%)
; peripheral arterial disease (6%), previous stroke or TIA (11%), microalbuminuria,
obesity, hyperlipidaemia
Interventions Beta-blocker group:
Step 1: atenolol 50 mg
Step 2: atenolol 100 mg
Step 3: atenolol 100 mg + bendroflumethiazide 1.25 mg + potassium
Step 4: atenolol 100 mg + bendroflumethiazide 2.5 mg + potassium
Step 5: atenolol 100 mg + bendroflumethiazide 2.5 mg + potassium + doxazosin gas-
trointestinal transport system 4 mg
Step 6: atenolol 100 mg + bendroflumethiazide 2.5 mg + potassium + doxazosin gas-
trointestinal transport system 8 mg
Further treatment to achieve BP goal added, as required
Calcium-channel blocker group:
Step 1: amlodipine 5 mg
Step 2: amlodipine 10 mg
Step 3: amlodipine 10 mg + perindopril 4 mg
Step 4: amlodipine 10 mg + perindopril 8 mg (2 × 4 mg)
Step 5: amlodipine 10 mg + perindopril 8 mg (2 × 4 mg) + doxazosin gastrointestinal
transport system 4 mg
Step 6: amlodipine 10 mg + perindopril 8 mg (2 × 4 mg) + doxazosin gastrointestinal
transport system 8 mg
Further treatment to BP goal added, as required.
On average, of total time, 79%were taking atenolol and 83%were taking amlodipine. At
the end of the study, 9% were taking atenolol monotherapy and 15% taking amlodipine
monotherapy
Outcomes Primary outcome: combined endpoint of non-fatal MI (including silent MI) and fatal
CHD
Secondary outcomes: all-cause mortality, total stroke, primary endpoint minus silentMI,
all coronary events, total cardiovascular events and procedures, cardiovascular mortality,
and non-fatal and fatal heart failure
Tertiary outcomes: silent MI, unstable angina, chronic stable angina, peripheral arterial
disease, life-threatening arrhythmias, development of diabetes, development of renal
impairment, and the effects on the primary endpoint and on total cardiovascular events
and procedures among prespecified subgroups
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
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ASCOT 2005 (Continued)
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 0.3%withdrew consent and 0.3%were lost
to follow-up. Not indicated whether rea-
sons for missing outcome data were similar
across treatment groups
Selective reporting (reporting bias) Low risk Reported all outcomes as stated in protocol
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
Berglund 1981
Methods Single-centre study
Randomisation: described as randomised controlled trial, but method of allocating par-
ticipants to treatment was not described
Blinding: not known if participants, providers, or assessors blinded
Loss to follow-up: 7%
Mean duration of follow-up: 10 years
Analyses: by intention-to-treat
Participants Geographic region: Sweden
Study setting: hospital
Number of participants: 106 (all men)
Age range: 47 to 54 years (mean: 50.8 years)
Race: not reported
BP at entry: > 170/105 mmHg
Comorbid conditions: not mentioned
Interventions Beta-blocker group:
Step 1: propranolol 80 mg twice daily
Step 2: propranolol 160 mg twice daily
Step 3: propranolol 160 mg twice daily + hydralazine 25 mg to 50 mg twice daily
Step 4: propranolol 160 mg twice daily + hydralazine 25 mg to 50 mg twice daily + other
antihypertensive drugs
Diuretic group:
Step 1: bendroflumethiazide 2.5 mg once daily
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Berglund 1981 (Continued)
Step 2: bendroflumethiazide 5 mg once daily
Step 3: bendroflumethiazide 5 mg once daily + hydralazine 25 mg to 50 mg twice daily
Step 4: bendroflumethiazide 5 mg once daily + hydralazine 25 mg to 50 mg twice daily
+ other antihypertensive drugs
At the end of trial, 74% were taking propranolol and 70% were taking bendroflumethi-
azide; with 42% taking propranolol and 40% taking bendroflumethiazide monotherapy
Outcomes Total mortality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Described as randomised controlled trial,
but method of allocating participants to
treatment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Completely unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk There was no blinding of outcome assess-
ment, but the outcome assessed (i.e. death)
is unlikely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 7%. Not indicated
whether reasons for missing outcome data
were similar across treatment groups
Selective reporting (reporting bias) Unclear risk No access to the protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
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Coope 1986
Methods Multicentre study
Randomisation: participants were randomised on a 50:50 basis without stratification
using random number tables. Opaque envelopes were supplied in sequence from the
trial administrative centre that gave instructions for allocation to treatment or control
group
Loss to follow-up: not stated
Mean duration of follow-up: 4.4 years
Participants Geographic region: England and Wales
Study setting: primary care
Number of participants: 884 (31% men)
Age range: 60 to 79 years (mean: 65 years)
Race: not stated
Exclusion criteria: atrial fibrillation, A-V heart block, ventricular failure, bronchial
asthma, diabetes mellitus (needing pharmacological treatment) or any serious concomi-
tant disease, and untreated hypertension with levels persistently > 280 mmHg for SBP or
120 mmHg for DBP or people already being treated for hypertension (within 3 months)
Mean BP at entry: 196.4/98.8 mmHg
BP entry criteria: not stated
Comorbid conditions: smoking 215 (24%)
Interventions Beta-blocker group:
Step 1: atenolol 100 mg/day
Step 2: bendrofluazide 5 mg/day
Step 3: methyldopa 500 mg/day
Step 4: any other recognised therapy such as nifedipine retard 20 mg twice daily
Control group:
No treatment
Proportion on assigned treatment at end of study: beta-blocker group: 70%
Outcomes Total mortality
CHD mortality: fatal MI, sudden death
CHD morbidity: non-fatal MI
Cerebrovascular mortality: fatal stroke
Cerebrovascular morbidity: non-fatal stroke
Cardiovascular mortality: fatal stroke, MI, sudden death, ventricular failure, ruptured
aneurysm, hypertensive nephropathy
Cardiovascular morbidity: non-fatal stroke, MI, non-fatal ventricular failure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random number table
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Coope 1986 (Continued)
Allocation concealment (selection bias) Low risk Used opaque sequentially numbered en-
velopes supplied by the trial administrative
centre
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not indicated whether reasons for missing
outcome data were similar across treatment
groups
Selective reporting (reporting bias) Unclear risk No access to protocol
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
ELSA 2002
Methods Multicentre study
Randomisation: computer-generated, using separate lists for each centre with a block size
of 4. Participants and study personnel, excluding the Safety Committee, were blinded
to treatment assignment for study duration
Loss to follow-up: 3.9%
Mean duration of follow-up: 3.75 years
Analyses: by intention-to-treat
Participants Geographic location: France, Germany, Greece, Italy, Spain, Sweden, UK
Study setting: 410 clinical units
Number of participants: 2334 (54.8% men)
Age range: 45 to 75 years (mean: 56 years)
Entry criteria: sitting SBP150mmHg to 210mmHg andDBP95mmHg to115mmHg,
fasting serum total cholesterol concentration ≤ 320 mg/dL, fasting serum triglyceride
concentration ≤ 300 mg/dL, and serum creatinine concentration ≤ 1.7 mg/dL
Race: 98.2% white
Main exclusion criteria: recent MI or stroke and insulin-dependent diabetes mellitus
Mean BP at entry: 163.5/101.3 mmHg
Comorbid conditions: current smoking (20.5%), ≥ 1 plaque (64%), previous antihy-
pertensive therapy (63%), diabetes, hyperlipidaemia
38Beta-blockers for hypertension (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
ELSA 2002 (Continued)
Interventions Beta-blocker group:
Atenolol 50 mg once daily
Calcium-channel blocker group:
Lacidipine 4 mg once daily
If satisfactory BP control was not achieved, lacidipine could be increased to 6 mg and
atenolol to 100 mg (month 1), with open-label hydrochlorothiazide added (12.5 mg/
day (month 3) and 25 mg/day (month 6))
Outcomes Change in mean maximum intima-media thickness
Plaque number
Fatal and non-fatal cardiovascular events
Total mortality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence computer-gener-
ated
Allocation concealment (selection bias) Unclear risk Not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 3.9%. Not indicated
whether reasons for missing outcome data
were similar across treatment groups
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
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HAPPHY 1987
Methods Multicentre study
Randomisation: participants were divided into 3 groups according to predicted CHD
risk based on a serum cholesterol, smoking habits, and SBP. Each risk group was divided
into 3 age strata and participants in the 9 groups were allocated to treatment at random.
Allocation method not described
Blinding: participants and providers not blinded, assessors blinded
Loss to follow-up: 1%
Mean duration of follow-up: 45.1 months
Analyses: by intention-to-treat
Participants Geographic region (% participant-years): Belgium (0.8%), Canada (4.8%), Czechoslo-
vakia (1.9%), Denmark (0.6%), Finland (14.0%), France (1.0%), Germany (3.3%),
Greece (0.3%), Iceland (3.6%), Italy (2.7%), the Netherlands (1.6%), Norway (1.8%),
Sweden (39.4%), UK (15.6%), USA (8.4%)
Study setting: primary care
Number of participants: 6569 (100% men)
Age range: 40 to 64 years (mean: 52.2 years)
Race: > 99% white
Exclusion criteria: history of MI, angina pectoris, stroke, malignant or secondary hyper-
tension, malignant disease, liver cirrhosis, alcoholism or other serious diseases; people
with absolute or relative contraindications to beta-blockers (chronic obstructive lung
disease) or thiazide diuretics (diabetes mellitus or gout); and people with other non-
hypertensive conditions requiring treatment with beta-blockers or diuretics
Mean BP at entry: 166/107 mmHg
BP entry criteria: diastolic BP 100 mmHg to 130 mmHg
Comorbid conditions: smoking 2266 (34.5%)
Interventions Beta-blocker group:
Step 1: atenolol 100 mg/day or metoprolol 200 mg/day; (until 1981) - atenolol 200 mg/
day or metoprolol 400 mg/day. Propranolol 160 mg/day given to 46 participants in 1
centre
Diuretic group:
Step 1: bendroflumethiazide 5 mg/day or hydrochlorothiazide 50 mg/day; (until 1981)
- bendroflumethiazide 10 mg/day or hydrochlorothiazide 100 mg/day
Additional treatment for both groups:
Step 2: hydralazine 75 mg/day
Step 3: hydralazine 150 mg/day
Step 4: step 3 + spironolactone 75 mg/day
Step 5: step 3 + spironolactone 150 mg/day
Step 6: step 5 + optional drug
Percentage on assigned treatment at end of study: beta-blocker group: 85.9% (68% as
monotherapy); diuretic group: 83.4% (62% as monotherapy)
Outcomes Total mortality - death from any cause
CHD mortality - fatal MI, sudden death
CHD morbidity - non-fatal MI
Cerebrovascular mortality - fatal stroke
Cerebrovascular morbidity - non-fatal stroke
Cardiovascular mortality - fatal stroke, MI
Cardiovascular morbidity - non-fatal stroke, non-fatal MI
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HAPPHY 1987 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 1%. Not indicated
whether reasons for missing outcome data
were similar across treatment groups
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
INVEST 2003
Methods Multicentre study
Randomisation: Internet-basedmanagement system automatically randomised each par-
ticipant to a treatment strategy. Randomisation scheme used a standard C routine and
blocked by site using randomly permuted block sizes of 4 and 6. Randomisation result
was automatically stored in the central database as part of the participant’s record and
was also returned to the site investigator for electronic signature of strategy drugs in
accordance with the protocol
Blinding: not clear whether participants were blinded; provider not blinded; assessor
blinded
Mean duration of follow-up: 2.7 years
Analyses: by intention-to-treat
Participants Geographic location: Australia, Canada, Cuba, Dominican Republic, El Salvador, Ger-
many, Guatemala, Hungary, Italy, Mexico, New Zealand, Panama, Turkey, US
Study setting: primary care
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INVEST 2003 (Continued)
Number of participants: 22,576 (47.9% men)
Age: ≥ 50 years (mean 66.1 years)
Entry criteria: sitting BP > 140/90 mmHg and documented coronary artery disease;
mean entry BP 149.5/86.3 mmHg (SD 19.7/12.0)
Race: 48.4% white, 13.4% black, 35.6% Hispanic, 0.7% Asian
Exclusion criteria: people taking beta-blockers within 2weeks of randomisation or taking
beta-blockers for an MI that occurred in the previous 12 months
Comorbid conditions: current smokers (12.4%), hypercholesterolaemia (55.8%), dia-
betes (28.3%), prior MI or abnormal angiogram (53.0%), previous stroke (5.1%), LVH
(21.9%)
Interventions Beta-blocker group:
Step 1: atenolol 50 mg/day
(added trandolapril 2 mg/day for participants with diabetes, renal impairment, or heart
failure)
Step 2: atenolol 50 mg/day + hydrochlorothiazide 25 mg/day
Step 3: atenolol 50 mg twice day + hydrochlorothiazide 25 mg twice daily
Step 4: atenolol 50 mg twice day + hydrochlorothiazide 25 mg twice daily + trandolapril
2 mg/day
Step 5: maximum tolerated or add non-study antihypertensive medication, or both.
Titration ranges: atenolol 25 mg/day to 200 mg/day, hydrochlorothiazide 12.5 mg/day
to 100 mg/day, trandolapril 1 mg/day to 8 mg/day, verapamil SR 120 mg/day to 480
mg/day
Calcium-channel blocker group:
Step 1: verapamil SR 240 mg/day
(added trandolapril 2 mg/day for participants with diabetes, renal impairment, or heart
failure)
Step 2: verapamil SR 240 mg/day + trandolapril 2 mg/day
Step 3: verapamil SR 180 mg twice daily + trandolapril 2 mg twice daily
Step 4: verapamil SR 180mg twice daily + trandolapril 2mg twice daily + hydrochloroth-
iazide 25 mg/day
Step 5: maximum tolerated or add non-study antihypertensive medication, or both.
Titration ranges: atenolol 25 mg/day to 200 mg/day, hydrochlorothiazide 12.5 mg/day
to 100 mg/day, trandolapril 1 mg/day to 8 mg/day, verapamil SR 120 mg/day to 480
mg/day
Percentage on assigned treatment at end of study: beta-blocker group: 77.5% (18.1% as
monotherapy); calcium-channel blocker group: 81.5% (17.4% as monotherapy)
Outcomes Primary: first occurrence of death from any cause, non-fatal MI, or non-fatal stroke
Secondary: all-cause death, non-fatal MI, non-fatal stroke, cardiovascular death, angina,
cardiovascular hospitalisations, BP control, cancer, Alzheimer’s disease, Parkinson’s dis-
ease, gastrointestinal bleeding
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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INVEST 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated (assumed to be com-
puter-generated, because it is a blocked ran-
domisation with varying block sizes)
Allocation concealment (selection bias) Low risk Central allocation (web-based randomisa-
tion: an Internet-based management sys-
tem automatically randomised each partic-
ipant to a treatment strategy)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clear whether participants were
blinded; provider not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not indicated whether reasons for missing
outcome data were similar across treatment
groups
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
IPPPSH 1985
Methods Multicentre study
Randomisation: random allocation of participants was achieved by providing to the in-
vestigating centres participant numbers randomised into balanced blocks each having 6
numbers. Sealed envelopes containing the treatment code were provided to each inves-
tigator
Loss to follow-up: 0.6%
Duration of follow-up: 3 to 5 years (mean 4 years)
Participants Geographic region: UK (36.4%), Canada (12.0%), the Netherlands (3.6%), Israel (20.
9%), Italy (11.7%), Federal Republic of Germany (15.4%)
Number of participants: 6357 (50.2% men)
Age range: 40 to 64 years (mean age: 52.2 years)
Entry BP criteria: diastolic BP of 100 mmHg to 125 mmHg (Korotkoff Phase V)
measured in seated position using standard mercury sphygmomanometer;
mean SBP at entry 173 mmHg (SD 18.4)
Race:
Exclusion criteria: past or present history of angina pectoris or MI; heart failure; relevant
cardiac valvular disease; atrio-ventricular blocks grades II and III or sick sinus syndrome;
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bradycardia (< 50 beats per minute); intermittent claudication; previous cerebrovascular
accident; insulin-dependent diabetes; pregnancy; obstructive airways disease or history
of bronchial asthma; renal, hepatic, gastrointestinal or any other severe disease
Comorbid conditions: current smokers (29.1%)
Interventions Beta-blocker group:
Step 1: oxprenolol slow release 160 mg/day
Control group:
Step 1: film-coated placebo of identical appearance
Additional treatment for both groups:
Step 2: diuretic or sympatholytic or vasodilator
Step 3: diuretic + sympatholytic, or diuretic + vasodilator, or sympatholytic + vasodilator
Step 4: diuretic + sympatholytic + vasodilator
During study, 30% of participants remained on beta-blocker only while 15% remained
placebo only. Total diuretic use was 67% in the beta-blocker group and 82% in the
placebo group
Outcomes CHD mortality: fatal MI, sudden death
CHD morbidity - non-fatal MI
Cerebrovascular mortality - fatal stroke
Cerebrovascular morbidity - non-fatal stroke
Cardiovascular mortality
Cardiovascular morbidity
Total mortality
Adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation used so assumed to be
computer-generated
Allocation concealment (selection bias) Low risk Random allocation of participants was
achieved by providing to the investigating
centres participant numbers randomised
into balanced blocks each having 6 num-
bers. Sealed envelopes containing the treat-
ment code were provided to each investiga-
tor
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded
Blinding of outcome assessment (detection
bias)
Low risk Blind outcome assessment
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All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not indicated whether reasons for missing
outcome data were similar across treatment
groups
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
LIFE 2002
Methods Multicentre study. 2-week run-in placebo period
Randomisation: allocation numbers assigned with treatment groups using a computer-
generated allocation schedule; participants were classed as assigned to a group when they
had received an allocation number. All participants receivedmasked losartan andmasked
atenolol, 1 active and 1 placebo tablet
Blinding: participants, providers, and outcome assessors blinded
Mean duration of follow-up: 4.8 years (SD 0.9)
Analyses: by intention-to-treat
Participants Geographic region: Scandinavia, UK and USA
Study setting: 945 clinical centres, mostly primary care except in Denmark where most
participants were referred to hospital-based centres.
9222 randomised but 29 participants at 1 centre excluded for irregularities. 9193 (46%
men): Denmark (15%), Finland (16%), Iceland (1%), Norway (15%), Sweden (24%),
UK (9%), USA (19%)
Age range: 55 to 80 years
BP entry criteria: DBP 95 mmHg to 115 mmHg or SBP 160 mmHg to 200 mmHg
Race: 92% white, 6% black
Exclusion criteria: secondary hypertension, MI or stroke within the previous 6 months;
angina pectoris requiring treatment with beta-blockers or calcium-channel blockers;
heart failure or left ventricular ejection fraction of≤ 40%; a disorder requiring treatment
with angiotensin-II antagonist, beta-blocker, hydrochlorothiazide, or ACE inhibitor
Comorbid conditions: LVH (100%), smoking (16%), diabetes (13%), previous MI
(16%), previous stroke (8%), atrial fibrillation (4%), peripheral vascular disease (6%)
Interventions Beta-blocker group:
Step 1: atenolol 50 mg/day and losartan placebo daily
Angiotensin-II antagonist group:
Step 2: losartan 50 mg/day and atenolol placebo daily
Additional treatment for both groups:
Step 2: add hydrochlorothiazide 12.5 mg/day
Step 3: double dose of Step 1 therapy, atenolol 100 mg/day or losartan 100 mg/day +
hydrochlorothiazide 12.5 mg/day
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Step 4: add other antihypertensive drugs excluding ACE inhibitors, angiotensin-II an-
tagonists and beta-blockers
Participants on assigned treatment at end of follow-up: losartan group: 84%, atenolol
group: 80%
Outcomes Primary: CVD mortality and mortality (composite endpoint of cardiovascular death,
MI, and stroke)
Secondary: total mortality, angina pectoris, or CHF requiring hospital admission
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation sequence
Allocation concealment (selection bias) Unclear risk Method not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal loss to follow-up
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs were added
to randomly allocated treatment to control
BP. The observed effects may equally have
resulted from the different additional drugs
MRC 1985
Methods Multicentre study
Randomisation: stratified blocks of 8 within each sex, 10-year age group and clinic
Blinding: participants and outcome assessors blinded, providers not blinded
Loss to follow-up: 19%
Mean duration of follow-up: 4.9 years
Analyses: by intention-to-treat
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Participants Geographic region: England, Scotland, and Wales
Study setting: primary care
Number of participants: 17,354 (52% men)
Age range: 35 to 64 years (mean: 52 years)
Race: not stated
Exclusion criteria: secondary hypertension; taking antihypertensive treatment; normally
accepted indications for antihypertensive treatment (such as congestive cardiac failure)
present; MI or stroke within the previous 3 months; presence of angina, intermittent
claudication, diabetes, gout, bronchial asthma, serious intercurrent disease, or pregnancy
Mean BP at entry: 162/98 mmHg
BP entry criteria: SBP < 200 mmHg and DBP 90 to 109 mmHg
Comorbid conditions: smoking 29%
Interventions Control:
Matching placebo
Beta-blocker group:
Propranolol up to 240 mg
Supplementary drug: methyldopa (guanethidine used initially)
Diuretic group:
Bendrofluazide 10 mg/day
Supplementary drug: methyldopa
Percentage on assigned therapy at study end: beta-blocker group: 59%, diuretic group:
61.8%, placebo group: 56.3%
Outcomes Total mortality: death from any cause
CHD mortality - fatal MI, sudden death
CHD morbidity - non-fatal MI
Cerebrovascular mortality - fatal stroke
Cerebrovascular morbidity - non-fatal stroke
Cardiovascular mortality - fatal stroke, MI, sudden death
Cardiovascular morbidity - non-fatal stroke, MI, ruptured aneurysms, and others
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Method not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants blinded, but providers not
blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up (19%)
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
MRCOA 1992
Methods Multicentre study
Randomisation: stratified blocks of 8 within each sex and clinic
Blinding: participants and outcome assessors blinded, providers not blinded
Loss to follow-up: 25%
Mean duration of follow-up: 5.8 years
Analyses: by intention-to-treat
Participants Geographic region: England, Scotland, and Wales
Study setting: primary care
Number of participants: 4396 (42% men)
Age range: 65 to 74 years (mean: 70.3 years)
Race: not reported
Exclusion criteria: known or suspected secondary hypertension; taking antihypertensive
drugs; cardiac failure or any other accepted indication for antihypertensive treatment;
receiving treatment for angina pectoris; history of MI or stroke within the preceding 3
months; impaired renal function; diabetic asthma; serious intercurrent disease, including
malignancy known to be present at time of examination; serum potassium concentration
≤ 3.4 mmol/L or > 5.0 mmol/L
Mean BP at entry: 184/91 mmHg
BP entry criteria: SBP 160 mmHg to 209 mmHg and DBP < 115 mmHg
Comorbid conditions: smoking: 17.5%
Interventions Control group:
Matching placebo
Beta-blocker group:
Step 1: atenolol 50 mg/day, may be increased to 100 mg/day
Step 2: amiloride 2.5 mg/day + hydrochlorothiazide 25 mg/day or amiloride 5 mg/day
+ hydrochlorothiazide 50 mg/day
Step 3: nifedipine up to 20 mg/day
Step 4: other drugs
Diuretic group:
Step 1: amiloride 2.5 mg/day + hydrochlorothiazide 25 mg/day or amiloride 5 mg/day
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+ hydrochlorothiazide 50 mg/day
Step 2: atenolol 50 mg/day
Step 3: nifedipine up to 20 mg/day
Step 4: other drugs
Percentage on assigned treatment at end of study: beta-blocker group: 37%; diuretic
group: 52%; placebo group: 47%
Outcomes Total mortality: death from any cause
CHD mortality - fatal MI, sudden death
CHD morbidity - non-fatal MI
Cerebrovascular mortality - fatal stroke
Cerebrovascular morbidity - non-fatal stroke
Cardiovascular mortality - fatal stroke, MI, sudden death
Cardiovascular morbidity - non-fatal stroke, MI, CHF, TIAs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Method not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants blinded, but providers not
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up (25%)
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
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UKPDS-39-1998
Methods Multicentre study
Randomisation: included participants were part of the UKPDS involving allocation at
random to 1 of 3 therapeutic groups: less tight control (avoid beta-blockers and ACE
inhibitors) 33%; tight control (ACE inhibitor) 33%; tight control (beta-blocker) 33%.
Allocation concealment was done with opaque, sealed envelopes with a checkmaintained
on numerical sequence, dates of opening and results
Blinding: participants, providers, and assessors not blinded
Loss to follow-up: 4%
Median duration of follow-up: 8.4 years
Analyses: by intention-to-treat
Participants Geographic region: England, Scotland, and Northern Ireland
Study setting: primary care
Number of participants: 758 (54% men)
Age range: 25 to 65 years (mean: 56.4 years)
Race: white 651 (86%); black 62 (8%); Asian-Indian 39 (5%); other 6 (1%)
Exclusion criteria: ketonuria > 3 mmol/L; history of MI in the previous year; current
angina or heart failure; > 1 vascular episode; serum creatinine concentration > 175µmol/
L; retinopathy requiring laser treatment; malignant hypertension; uncorrected endocrine
abnormality; occupation which would preclude insulin treatment (such as heavy goods
vehicle driver); a severe concurrent illness likely to limit life or require extensive treatment;
or inadequate understanding or unwillingness to enter the study
Mean BP at entry: 159/93 mmHg
BP entry criteria: SBP ≥ 160 mmHg or DBP ≥ 90 mmHg, or both; or SBP ≥ 150
mmHg or DBP ≥ 85 mmHg in participants receiving antihypertensive medication
Comorbid conditions: smoking: 171 (23%)
Interventions Beta-blocker group:
Step 1: atenolol 50 mg/day, increasing to 100 mg/day
ACE inhibitor group:
Step 1: captopril 25 mg twice daily, increasing to 50 mg twice daily
Additional treatment for both groups:
Step 2: frusemide 20 mg/day (maximum 40 mg twice daily)
Step 3: nifedipine slow release 10 mg (maximum 40 mg) twice daily
Step 4: methyldopa 250 mg (maximum 500 mg) twice daily; prazosin 1 mg (maximum
5 mg) 3 times daily
Participants remaining on assigned therapy at study end: beta-blocker group: 65%, ACE
inhibitor group: 78%
Outcomes Total mortality: death from any cause
CHD mortality - fatal MI, sudden death
CHD morbidity - non-fatal MI
Cerebrovascular mortality - fatal stroke
Cerebrovascular morbidity - non-fatal stroke
Cardiovascular mortality - fatal stroke, MI, sudden death
Cardiovascular morbidity - non-fatal stroke, MI, heart failure
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random sequence
Allocation concealment (selection bias) Low risk Allocation concealment with opaque,
sealed envelopes with a check maintained
on numerical sequence, until dates of open-
ing and results
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and providers not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment, but
the outcome assessed (i.e. death) is unlikely
to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not indicated whether reasons for missing
outcome data were similar across treatment
groups
Selective reporting (reporting bias) Low risk All outcomes reported as stated in protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
VA COOP 1982
Methods Multicentre study
Randomisation: described as randomised controlled trial, but method of allocating par-
ticipants to treatment not described
Blinding: participants, providers, and assessors blinded
Loss to follow-up: 8%
Mean duration of follow-up: 12 months
Participants withdrawn from the study for uncontrolled BP not included in the analysis
Participants Geographic region: USA
Study setting: hospital
Number of participants: 683 (all men)
Age range: 21 to 65 years (mean: 49.6 years)
Race: 43% white and 57% black
BP at entry: DBP 95 to 104 mmHg
Comorbid conditions: not described
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Interventions Beta-blocker group:
Propranolol 40 mg twice daily, increasing to 640 mg/day
Diuretic group:
Hydrochlorothiazide 25 mg twice daily, increasing to 200 mg/day
Participants still on assigned baseline therapy at study end: beta-blocker group, 39%,
diuretic group: 52%
Outcomes Total mortality
Cerebrovascular disease
CHD
Notes Participants were withdrawn from the study if, on any follow-up visit, DBP ≥ 120
mmHg
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and providers blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A total of 73 (10.7%) of the patients were
dropped from the study after randomiza-
tion. Of these, 42 (57.5%) were in the
propranolol group and 31 were taking hy-
drochlorothiazide. The difference was not
significant”
Analyses by intention-to-treat
Selective reporting (reporting bias) Unclear risk No access to study protocol.
Other bias Unclear risk Other antihypertensive drugs added to ran-
domly allocated treatment to control BP.
The observed effects may equally have re-
sulted from the different additional drugs
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ACE: angiotensin-converting enzyme; BP: blood pressure; CHD: coronary heart disease; CHF: congestive heart failure; CVD: cardio-
vascular disease; DBP: diastolic blood pressure; LVH: left ventricular hypertrophy; MI: myocardial infarction; SBP: systolic blood
pressure; SD: standard deviation; SR: sustained release; TIA: transient ischaemic attack.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACCORD 2010 Study designed to test the effect of BP lowering in addition to glycaemic control in people with diabetes.
Participants were assigned to 2 BP treatment goals - intensive (SBP < 120 mmHg) or standard (SBP < 140
mmHg). Various classes of antihypertensive drugs used but recommended start with combination of diuretic
and ACE inhibitor or beta-blocker. Beta-blockers not first-line or monotherapy
ADaPT 2008 Observational study conducted in primary care compared ACE inhibitor-based treatment (ramipril) with a
treatment based on diuretics or beta-blockers. Not randomised
APSIS 2006 Study compared verapamil or metoprolol in people with stable angina pectoris. Not all participants had
hypertension (27%). Mean baseline BP not given
CAPP 1999 This study compared the effects of ACE inhibitors and conventional therapy (diuretics and beta-blockers) on
cardiovascular morbidity and mortality in people with hypertension. Findings were not reported separately
for beta-blockers
CAPRICORN 2001 Trial evaluated the effects of carvedilol with placebo on survival in post-MI participants with left ventricular
dysfunction with or without symptomatic heart failure. All participants given ACE inhibitors for at least 48
hours before randomisation. Not all participants had hypertension (54%) and beta-blockers not first-line
or monotherapy
CARDHIAC 2008 Study examined effects of doxazosin GITS and atenolol on 3 measures of target organ damage in people
with type 2 diabetes and hypertension. Participants received ACE inhibitors or ARB and diuretic initially
before receiving doxazosin GITS and atenolol. Beta-blockers not first-line or monotherapy
CHHIPS 2009 This RCT, which was conducted in 6 centres in the UK, evaluated the effects of active treatment with the
ACE inhibitor, lisinopril, or beta-blocker, labetalol, compared to placebo in people aged > 18 years with a
clinical diagnosis of suspected stroke (with symptom onset < 36 hours) and hypertension (defined as SBP >
160 mmHg). After 2 weeks of treatment, study participants were routinely started on an ACE inhibitor with
or without a diuretic irrespective of whether they had normal BP or hypertension, unless they were deemed
to be unsuitable for such therapy.Decisions with regard to future antihypertensive therapywere delayed until
the end of the trial intervention (2 weeks). The proportion of participants on assigned treatment at the end
of the study was 71% in the beta-blocker group, 68% in the ACE inhibitor group, and 80% in the placebo
group. 172 participants, with mean age 74 years, were enrolled and the study reported mortality data at 3
months. We excluded this study because of the short duration (i.e. only 2 weeks) of relevant interventions
CIBIS-II 1999 Trial compared bisoprolol and placebo in people with heart failure receiving standard therapy with an ACE
inhibitor and diuretic. Not all participants had hypertension (mean baseline BP 139/80 mmHg) and beta-
blocker not first-line or monotherapy
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COMET 2003 Trial compared carvedilol and metoprolol in people with chronic heart failure. Not all had hypertension
(36%). Mean baseline BP 126/77 mmHg
CONVINCE 1998 The Controlled ONset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial is a
randomised, prospective, double-blind, parallel-group, 2-arm, multicentre, international trial. The study
recruited 15,000 people with hypertension, aged > 55 years, with an established second risk factor for
cardiovascular disease and followed them for 5 years to compare the effects of controlled onset-extended
release verapamil 180 mg/day and hydrochlorothiazide 12.5 mg/day or atenolol 50 mg/day. Data has not
been reported separately for hydrochlorothiazide and atenolol
COPE 2005 Study compared a combination of ARB, beta-blocker, or thiazide diuretic in addition to a calcium-channel
blocker, benidipine hydrochloride, in Japanese people with hypertension. Beta-blockers not first-line treat-
ment or monotherapy.
COPERNICUS 2004 Study compared carvedilol vs placebo in people with chronic heart failure and receiving spironolactone or
not at baseline. Not all participants had hypertension (mean baseline BP 123/76 mmHg)
COSMOS 2010 People with stage 1 or 2 hypertensionwere randomised evenly to 1 of 15 groups for 6 weeks: extended-release
carvedilol (carvedilol CR)monotherapy 20mg/day, 40mg/day, or 80mg/day; lisinoprilmonotherapy 10mg/
day, 20 mg/day, or 40 mg/day; or 1 of 9 combinations of carvedilol CR + lisinopril initiated simultaneously.
The study has not reported effects on mortality or cardiovascular endpoints
Dietz 2008 This RCT was conducted in 85 centres in China, Germany, India, South Africa, Spain, and Turkey. People
with hypertension (defined as mean sitting DBP 95 mmHg to 110 mmHg) were randomised to once-daily
aliskiren 150 mg (231 participants), atenolol 50 mg (231 participants), or the combination (150/50 mg;
232 participants) for 6 weeks, followed by a further 6 weeks on double the initial doses of aliskiren and
atenolol. Aliskiren is the first direct renin inhibitor to be approved for the treatment of hypertension. The
proportion of participants on assigned treatment at the end of the study was 92.2% in the beta-blocker
group, 91.3% in the direct renin inhibitor group, and 88.4% in the combination group. The trial followed
up 694 participants (mean age 55.2 years, 23% aged ≥ 65 years) for 12 weeks. We excluded this study
because of the short duration (i.e. only 12 weeks) of relevant interventions
Dutch TIA 1993 The trial evaluated the effects of a beta-blocker (atenolol) in people after a transient ischaemic attack or non-
disabling ischaemic stroke in 56 collaborative centres in the Netherlands. Participants were randomised to
atenolol or a matching placebo. The proportion of participants on assigned treatment in the beta-blocker
group was 71% at 2 years (and 64% at 3 years) and in the placebo group was 75% at 2 years (and 68% at 3
years). The trial followed up 1473 participants (52% aged > 65 years) for a mean duration of 2.7 years. We
excluded the trial because only 29% of participants had hypertension at baseline
GEMINI 2008 Trial compared effects of carvedilol with metoprolol on glycaemic control in people with hypertension and
type-2 diabetes. BP was stabilised using ACE inhibitors or ARB antihypertensive regimens (or both) prior
to randomisation. Beta-blockers not first-line or monotherapy
IMPACT-HF 2004 Study assessed the use of carvedilol therapy initiated before discharge in people hospitalised with heart
failure compared with ’usual care’. Not all participants had hypertension (64%). Baseline mean BP 124/69.
5 mmHg)
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(Continued)
MAPHY 1988 This multicentre study was a subset of the HAPPHY trial. Analysis take into consideration only 1 of the 2
beta-blockers (metoprolol). Including this trial alongside the HAPPHY trial would count those participants
twice
Marazzi 2011 This trial compared the effects of long-term treatment with nebivolol vs carvedilol on left ventricular ejection
fraction in people with hypertensive chronic heart failure. We excluded this study because the majority of
participants were already taking other antihypertensives at baseline, mainly ACE inhibitors
MERIT-HF 2002 Trial evaluated metoprolol compared to placebo added to standard therapy in people with heart failure. Not
all participants had hypertension (44%). Mean baseline BP not given
Nilsson 2007 This trial compared 2 first-line antihypertensive therapies for initiating treatment in hypertension, i.e. the
ACE inhibitor zofenopril and the beta-blocker atenolol. The study has not reported effects on mortality or
cardiovascular endpoints
NORDIL 2000 The Nordic Diltiazem (NORDIL) study enrolled 10,881 people with hypertension aged 50 to 74 years at
health centres in Norway and Sweden and randomly assigned them to either diltiazem, or diuretics with/
without beta-blockers. Morbidity and mortality were not reported separately for participants assigned to
beta-blocker therapy
REASON 2009 Trial compared the effects of atenolol and perindopril/indapamide on BP and carotid-femoral pulse wave
velocity, which is a marker for aortic stiffness and arterial wall alterations. No morbidity or mortality data
reported
RESOLVD 2000 Trial compared metoprolol or placebo in people with heart failure who had received treatment with either
an ACE inhibitor (enalapril) or ARB (candesartan) or both for 5 months prior to trial commencement (+ a
diuretic in 84% of participants). Beta-blocker not first-line or monotherapy
SENIORS 2005 Study compared the effects of nebivolol with placebo, in addition to standard therapy, in elderly people with
chronic heart failure. Not all participants had hypertension (62%). Mean baseline BP 139/81 mmHg
STOP 1991 This study compared the effects of active hypertensive treatment (1 of 3 beta-blockers or a diuretic) and
placebo in elderly people with hypertension. Morbidity and mortality were not reported separately for
participants assigned to beta-blocker therapy
STOP-2 1999 Conventional antihypertensive drugs (1 of 3 beta-blockers or a diuretic) were compared with newer agents,
ACE inhibitors and calcium-channel blockers. Findings were not reported separately for participants taking
beta-blockers
TEST 1995 The trial was conducted in 21 centres in Sweden between July 1988 and June 1992. The study evaluated
the effects of a beta-blocker (atenolol) in people aged > 40 years enrolled within 3 weeks of a stroke or
transient ischaemic attack. Participants were randomised to atenolol or a matching placebo. The proportion
of participants on assigned treatment at the end of the study not stated. The trial followed up 720 participants
(mean age 70.4 years) for a mean duration of 2.5 years. We excluded this study because not all participants
had hypertension at baseline
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ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; BP: blood pressure; DBP: diastolic blood pressure; MI:
myocardial infarction; RCT: randomised controlled trial; SBP: systolic blood pressure.
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D A T A A N D A N A L Y S E S
Comparison 1. Beta-blocker versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 4 23613 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.88, 1.11]
2 Total stroke 4 23613 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.66, 0.96]
3 Total coronary heart disease 4 23613 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.81, 1.07]
4 Cardiovascular death 4 23613 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.80, 1.09]
5 Total cardiovascular disease 4 23613 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.79, 0.97]
6 Withdrawal due to adverse
effects
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Oxprenolol 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Propranolol 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Atenolol 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Beta-blocker versus diuretic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 5 18241 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.91, 1.19]
2 Total stroke 4 18135 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.65, 2.09]
2.1 Cardio-selective beta-
blocker
3 9435 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.55, 1.54]
2.2 Non-selective beta-blocker 1 8700 Risk Ratio (M-H, Random, 95% CI) 2.28 [1.31, 3.95]
3 Total coronary heart disease 4 18135 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.82, 1.54]
3.1 Aged < 65 years 3 15952 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.17]
3.2 Aged > 65 years 1 2183 Risk Ratio (M-H, Random, 95% CI) 1.63 [1.15, 2.32]
4 Cardiovascular death 3 17452 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.90, 1.32]
5 Total cardiovascular disease 4 18135 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.99, 1.28]
6 Withdrawal due to adverse
effects
3 11566 Risk Ratio (M-H, Random, 95% CI) 1.69 [0.95, 3.00]
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Comparison 3. Beta-blocker versus calcium-channel blocker (CCB)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 4 44825 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [1.00, 1.14]
2 Total stroke 3 44167 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.11, 1.40]
3 Total coronary heart disease 3 44167 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.96, 1.15]
4 Cardiovascular death 4 44825 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.92, 1.46]
5 Total cardiovascular disease 2 19915 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.08, 1.29]
6 Withdrawal due to adverse
effects
2 21591 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.71, 2.04]
Comparison 4. Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 3 10828 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.24]
2 Total stroke 2 9951 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [1.11, 1.53]
3 Total coronary heart disease 2 9951 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.76, 1.06]
4 Cardiovascular death 3 10828 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.92, 1.29]
5 Total cardiovascular disease 3 10828 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.72, 1.38]
5.1 Angiotensin-converting
enzyme inhibitors
2 1635 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.63, 1.04]
5.2 Angiotensin receptor
blockers
1 9193 Risk Ratio (M-H, Random, 95% CI) 1.16 [1.04, 1.30]
6 Withdrawal due to adverse
effects
2 9951 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [1.29, 1.54]
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Analysis 1.1. Comparison 1 Beta-blocker versus placebo or no treatment, Outcome 1 Mortality.
Review: Beta-blockers for hypertension
Comparison: 1 Beta-blocker versus placebo or no treatment
Outcome: 1 Mortality
Study or subgroup Beta-blocker Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IPPPSH 1985 108/3185 114/3172 20.4 % 0.94 [ 0.73, 1.22 ]
MRC 1985 120/4403 253/8654 30.5 % 0.93 [ 0.75, 1.15 ]
Coope 1986 60/419 69/465 11.7 % 0.97 [ 0.70, 1.33 ]
MRCOA 1992 167/1102 315/2213 37.4 % 1.06 [ 0.90, 1.27 ]
Total (95% CI) 9109 14504 100.0 % 0.99 [ 0.88, 1.11 ]
Total events: 455 (Beta-blocker), 751 (Placebo)
Heterogeneity: Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Beta-blocker versus placebo or no treatment, Outcome 2 Total stroke.
Review: Beta-blockers for hypertension
Comparison: 1 Beta-blocker versus placebo or no treatment
Outcome: 2 Total stroke
Study or subgroup Beta-blocker Pacebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IPPPSH 1985 45/3185 46/3172 18.4 % 0.97 [ 0.65, 1.47 ]
MRC 1985 42/4403 109/8654 29.4 % 0.76 [ 0.53, 1.08 ]
Coope 1986 23/419 44/465 16.7 % 0.58 [ 0.36, 0.94 ]
MRCOA 1992 56/1102 134/2213 35.6 % 0.84 [ 0.62, 1.14 ]
Total (95% CI) 9109 14504 100.0 % 0.80 [ 0.66, 0.96 ]
Total events: 166 (Beta-blocker), 333 (Pacebo)
Heterogeneity: Chi2 = 2.76, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Beta-blocker versus placebo or no treatment, Outcome 3 Total coronary heart
disease.
Review: Beta-blockers for hypertension
Comparison: 1 Beta-blocker versus placebo or no treatment
Outcome: 3 Total coronary heart disease
Study or subgroup Beta-blocker Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IPPPSH 1985 98/3185 107/3172 26.4 % 0.91 [ 0.70, 1.19 ]
MRC 1985 103/4403 234/8654 38.8 % 0.87 [ 0.69, 1.09 ]
Coope 1986 35/419 38/465 8.9 % 1.02 [ 0.66, 1.59 ]
MRCOA 1992 80/1102 159/2213 26.0 % 1.01 [ 0.78, 1.31 ]
Total (95% CI) 9109 14504 100.0 % 0.93 [ 0.81, 1.07 ]
Total events: 316 (Beta-blocker), 538 (Placebo)
Heterogeneity: Chi2 = 0.98, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Beta-blocker versus placebo or no treatment, Outcome 4 Cardiovascular death.
Review: Beta-blockers for hypertension
Comparison: 1 Beta-blocker versus placebo or no treatment
Outcome: 4 Cardiovascular death
Study or subgroup Beta-blocker Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IPPPSH 1985 45/3185 56/3172 17.7 % 0.80 [ 0.54, 1.18 ]
MRC 1985 65/4403 139/8654 29.6 % 0.92 [ 0.69, 1.23 ]
Coope 1986 35/419 50/465 15.0 % 0.78 [ 0.51, 1.17 ]
MRCOA 1992 95/1102 180/2213 37.8 % 1.06 [ 0.84, 1.34 ]
Total (95% CI) 9109 14504 100.0 % 0.93 [ 0.80, 1.09 ]
Total events: 240 (Beta-blocker), 425 (Placebo)
Heterogeneity: Chi2 = 2.47, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Beta-blocker versus placebo or no treatment, Outcome 5 Total cardiovascular
disease.
Review: Beta-blockers for hypertension
Comparison: 1 Beta-blocker versus placebo or no treatment
Outcome: 5 Total cardiovascular disease
Study or subgroup Beta-blocker Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
IPPPSH 1985 143/3185 153/3172 21.6 % 0.93 [ 0.75, 1.16 ]
MRC 1985 146/4403 352/8654 33.4 % 0.82 [ 0.67, 0.99 ]
Coope 1986 82/419 121/465 16.1 % 0.75 [ 0.59, 0.96 ]
MRCOA 1992 151/1102 309/2213 28.9 % 0.98 [ 0.82, 1.18 ]
Total (95% CI) 9109 14504 100.0 % 0.88 [ 0.79, 0.97 ]
Total events: 522 (Beta-blocker), 935 (Placebo)
Heterogeneity: Chi2 = 3.81, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Beta-blocker versus placebo or no treatment, Outcome 6 Withdrawal due to
adverse effects.
Review: Beta-blockers for hypertension
Comparison: 1 Beta-blocker versus placebo or no treatment
Outcome: 6 Withdrawal due to adverse effects
Study or subgroup Beta-blocker Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Oxprenolol
IPPPSH 1985 719/3185 750/3172 0.95 [ 0.87, 1.04 ]
2 Propranolol
MRC 1985 518/4403 203/8654 5.02 [ 4.28, 5.87 ]
3 Atenolol
MRCOA 1992 333/1102 82/2213 8.16 [ 6.48, 10.27 ]
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Analysis 2.1. Comparison 2 Beta-blocker versus diuretic, Outcome 1 Mortality.
Review: Beta-blockers for hypertension
Comparison: 2 Beta-blocker versus diuretic
Outcome: 1 Mortality
Study or subgroup Beta-blocker Diuretic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berglund 1981 5/53 4/53 1.1 % 1.25 [ 0.36, 4.40 ]
MRC 1985 120/4403 128/4297 34.9 % 0.91 [ 0.72, 1.17 ]
HAPPHY 1987 96/3297 101/3272 27.3 % 0.94 [ 0.72, 1.24 ]
MRCOA 1992 167/1102 134/1081 36.4 % 1.22 [ 0.99, 1.51 ]
VA COOP 1982 1/340 1/343 0.3 % 1.01 [ 0.06, 16.06 ]
Total (95% CI) 9195 9046 100.0 % 1.04 [ 0.91, 1.19 ]
Total events: 389 (Beta-blocker), 368 (Diuretic)
Heterogeneity: Chi2 = 3.87, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Beta-blocker versus diuretic, Outcome 2 Total stroke.
Review: Beta-blockers for hypertension
Comparison: 2 Beta-blocker versus diuretic
Outcome: 2 Total stroke
Study or subgroup Beta-blocker Diuretic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardio-selective beta-blocker
VA COOP 1982 0/340 3/343 3.5 % 0.14 [ 0.01, 2.78 ]
HAPPHY 1987 32/3297 42/3272 32.4 % 0.76 [ 0.48, 1.19 ]
MRCOA 1992 56/1102 45/1081 34.4 % 1.22 [ 0.83, 1.79 ]
Subtotal (95% CI) 4739 4696 70.3 % 0.92 [ 0.55, 1.54 ]
Total events: 88 (Beta-blocker), 90 (Diuretic)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.12, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.31 (P = 0.76)
2 Non-selective beta-blocker
MRC 1985 42/4403 18/4297 29.7 % 2.28 [ 1.31, 3.95 ]
Subtotal (95% CI) 4403 4297 29.7 % 2.28 [ 1.31, 3.95 ]
Total events: 42 (Beta-blocker), 18 (Diuretic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
Total (95% CI) 9142 8993 100.0 % 1.17 [ 0.65, 2.09 ]
Total events: 130 (Beta-blocker), 108 (Diuretic)
Heterogeneity: Tau2 = 0.22; Chi2 = 11.08, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 5.54, df = 1 (P = 0.02), I2 =82%
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Analysis 2.3. Comparison 2 Beta-blocker versus diuretic, Outcome 3 Total coronary heart disease.
Review: Beta-blockers for hypertension
Comparison: 2 Beta-blocker versus diuretic
Outcome: 3 Total coronary heart disease
Study or subgroup Beta-blocker Diuretic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aged < 65 years
VA COOP 1982 2/340 2/343 2.4 % 1.01 [ 0.14, 7.12 ]
MRC 1985 103/4403 119/4297 33.8 % 0.84 [ 0.65, 1.10 ]
HAPPHY 1987 138/3297 125/3272 35.2 % 1.10 [ 0.86, 1.39 ]
Subtotal (95% CI) 8040 7912 71.4 % 0.97 [ 0.81, 1.17 ]
Total events: 243 (Beta-blocker), 246 (Diuretic)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Aged > 65 years
MRCOA 1992 80/1102 48/1081 28.6 % 1.63 [ 1.15, 2.32 ]
Subtotal (95% CI) 1102 1081 28.6 % 1.63 [ 1.15, 2.32 ]
Total events: 80 (Beta-blocker), 48 (Diuretic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0056)
Total (95% CI) 9142 8993 100.0 % 1.12 [ 0.82, 1.54 ]
Total events: 323 (Beta-blocker), 294 (Diuretic)
Heterogeneity: Tau2 = 0.06; Chi2 = 8.90, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 6.70, df = 1 (P = 0.01), I2 =85%
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Analysis 2.4. Comparison 2 Beta-blocker versus diuretic, Outcome 4 Cardiovascular death.
Review: Beta-blockers for hypertension
Comparison: 2 Beta-blocker versus diuretic
Outcome: 4 Cardiovascular death
Study or subgroup Beta-blocker Diuretic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MRC 1985 65/4403 69/4297 35.5 % 0.92 [ 0.66, 1.29 ]
HAPPHY 1987 57/3297 60/3272 30.6 % 0.94 [ 0.66, 1.35 ]
MRCOA 1992 95/1102 66/1081 33.9 % 1.41 [ 1.04, 1.91 ]
Total (95% CI) 8802 8650 100.0 % 1.09 [ 0.90, 1.32 ]
Total events: 217 (Beta-blocker), 195 (Diuretic)
Heterogeneity: Chi2 = 4.42, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Beta-blocker versus diuretic, Outcome 5 Total cardiovascular disease.
Review: Beta-blockers for hypertension
Comparison: 2 Beta-blocker versus diuretic
Outcome: 5 Total cardiovascular disease
Study or subgroup Beta-blocker Diuretic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VA COOP 1982 2/340 5/343 1.2 % 0.40 [ 0.08, 2.07 ]
MRC 1985 146/4403 140/4297 34.4 % 1.02 [ 0.81, 1.28 ]
HAPPHY 1987 170/3297 157/3272 38.2 % 1.07 [ 0.87, 1.33 ]
MRCOA 1992 151/1102 107/1081 26.2 % 1.38 [ 1.10, 1.75 ]
Total (95% CI) 9142 8993 100.0 % 1.13 [ 0.99, 1.28 ]
Total events: 469 (Beta-blocker), 409 (Diuretic)
Heterogeneity: Chi2 = 5.47, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Beta-blocker versus diuretic, Outcome 6 Withdrawal due to adverse effects.
Review: Beta-blockers for hypertension
Comparison: 2 Beta-blocker versus diuretic
Outcome: 6 Withdrawal due to adverse effects
Study or subgroup Beta-blocker Diuretic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MRC 1985 518/4403 462/4297 43.4 % 1.09 [ 0.97, 1.23 ]
MRCOA 1992 333/1102 160/1081 42.6 % 2.04 [ 1.72, 2.42 ]
VA COOP 1982 11/340 3/343 14.0 % 3.70 [ 1.04, 13.14 ]
Total (95% CI) 5845 5721 100.0 % 1.69 [ 0.95, 3.00 ]
Total events: 862 (Beta-blocker), 625 (Diuretic)
Heterogeneity: Tau2 = 0.19; Chi2 = 37.62, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Beta-blocker versus calcium-channel blocker (CCB), Outcome 1 Mortality.
Review: Beta-blockers for hypertension
Comparison: 3 Beta-blocker versus calcium-channel blocker (CCB)
Outcome: 1 Mortality
Study or subgroup Beta-blocker CCB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AASK 2002 38/441 13/217 1.1 % 1.44 [ 0.78, 2.64 ]
ELSA 2002 17/1157 13/1177 0.8 % 1.33 [ 0.65, 2.73 ]
INVEST 2003 893/11309 873/11267 53.3 % 1.02 [ 0.93, 1.11 ]
ASCOT 2005 820/9618 738/9639 44.9 % 1.11 [ 1.01, 1.22 ]
Total (95% CI) 22525 22300 100.0 % 1.07 [ 1.00, 1.14 ]
Total events: 1768 (Beta-blocker), 1637 (CCB)
Heterogeneity: Chi2 = 3.07, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Beta-blocker versus calcium-channel blocker (CCB), Outcome 2 Total stroke.
Review: Beta-blockers for hypertension
Comparison: 3 Beta-blocker versus calcium-channel blocker (CCB)
Outcome: 2 Total stroke
Study or subgroup Beta-blocker CCB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ELSA 2002 14/1157 9/1177 1.7 % 1.58 [ 0.69, 3.64 ]
INVEST 2003 201/11309 176/11267 34.4 % 1.14 [ 0.93, 1.39 ]
ASCOT 2005 422/9618 327/9639 63.8 % 1.29 [ 1.12, 1.49 ]
Total (95% CI) 22084 22083 100.0 % 1.24 [ 1.11, 1.40 ]
Total events: 637 (Beta-blocker), 512 (CCB)
Heterogeneity: Chi2 = 1.37, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Beta-blocker versus calcium-channel blocker (CCB), Outcome 3 Total coronary
heart disease.
Review: Beta-blockers for hypertension
Comparison: 3 Beta-blocker versus calcium-channel blocker (CCB)
Outcome: 3 Total coronary heart disease
Study or subgroup Beta-blocker CCB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ELSA 2002 17/1157 18/1177 2.1 % 0.96 [ 0.50, 1.85 ]
INVEST 2003 441/11309 452/11267 52.6 % 0.97 [ 0.85, 1.11 ]
ASCOT 2005 444/9618 390/9639 45.3 % 1.14 [ 1.00, 1.30 ]
Total (95% CI) 22084 22083 100.0 % 1.05 [ 0.96, 1.15 ]
Total events: 902 (Beta-blocker), 860 (CCB)
Heterogeneity: Chi2 = 2.95, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Beta-blocker versus calcium-channel blocker (CCB), Outcome 4 Cardiovascular
death.
Review: Beta-blockers for hypertension
Comparison: 3 Beta-blocker versus calcium-channel blocker (CCB)
Outcome: 4 Cardiovascular death
Study or subgroup Beta-blocker CCB Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AASK 2002 4/441 2/217 1.8 % 0.98 [ 0.18, 5.33 ]
ELSA 2002 8/1157 4/1177 3.5 % 2.03 [ 0.61, 6.74 ]
INVEST 2003 431/11309 431/11267 49.0 % 1.00 [ 0.87, 1.14 ]
ASCOT 2005 342/9618 263/9639 45.7 % 1.30 [ 1.11, 1.53 ]
Total (95% CI) 22525 22300 100.0 % 1.15 [ 0.92, 1.46 ]
Total events: 785 (Beta-blocker), 700 (CCB)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.56, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Beta-blocker versus calcium-channel blocker (CCB), Outcome 5 Total
cardiovascular disease.
Review: Beta-blockers for hypertension
Comparison: 3 Beta-blocker versus calcium-channel blocker (CCB)
Outcome: 5 Total cardiovascular disease
Study or subgroup Beta-blocker CCB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AASK 2002 13/441 4/217 0.7 % 1.60 [ 0.53, 4.85 ]
ASCOT 2005 937/9618 796/9639 99.3 % 1.18 [ 1.08, 1.29 ]
Total (95% CI) 10059 9856 100.0 % 1.18 [ 1.08, 1.29 ]
Total events: 950 (Beta-blocker), 800 (CCB)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.66 (P = 0.00026)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Beta-blocker versus calcium-channel blocker (CCB), Outcome 6 Withdrawal
due to adverse effects.
Review: Beta-blockers for hypertension
Comparison: 3 Beta-blocker versus calcium-channel blocker (CCB)
Outcome: 6 Withdrawal due to adverse effects
Study or subgroup Beta-blocker CCB Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
ASCOT 2005 254/9618 162/9639 49.9 % 1.57 [ 1.29, 1.91 ]
ELSA 2002 173/1157 192/1177 50.1 % 0.92 [ 0.76, 1.11 ]
Total (95% CI) 10775 10816 100.0 % 1.20 [ 0.71, 2.04 ]
Total events: 427 (Beta-blocker), 354 (CCB)
Heterogeneity: Tau2 = 0.14; Chi2 = 15.26, df = 1 (P = 0.00009); I2 =93%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor, Outcome 1
Mortality.
Review: Beta-blockers for hypertension
Comparison: 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome: 1 Mortality
Study or subgroup Beta-blocker RAS inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UKPDS-39-1998 27/358 43/400 9.0 % 0.70 [ 0.44, 1.11 ]
AASK 2002 38/441 29/436 6.5 % 1.30 [ 0.81, 2.06 ]
LIFE 2002 431/4588 383/4605 84.6 % 1.13 [ 0.99, 1.29 ]
Total (95% CI) 5387 5441 100.0 % 1.10 [ 0.98, 1.24 ]
Total events: 496 (Beta-blocker), 455 (RAS inhibitor)
Heterogeneity: Chi2 = 4.31, df = 2 (P = 0.12); I2 =54%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor, Outcome 2 Total
stroke.
Review: Beta-blockers for hypertension
Comparison: 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome: 2 Total stroke
Study or subgroup Beta-blocker RAS inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UKPDS-39-1998 17/358 21/400 7.9 % 0.90 [ 0.48, 1.69 ]
LIFE 2002 309/4588 232/4605 92.1 % 1.34 [ 1.13, 1.58 ]
Total (95% CI) 4946 5005 100.0 % 1.30 [ 1.11, 1.53 ]
Total events: 326 (Beta-blocker), 253 (RAS inhibitor)
Heterogeneity: Chi2 = 1.41, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 3.25 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor, Outcome 3 Total
coronary heart disease.
Review: Beta-blockers for hypertension
Comparison: 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome: 3 Total coronary heart disease
Study or subgroup Beta-blocker RAS inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UKPDS-39-1998 48/358 73/400 25.9 % 0.73 [ 0.53, 1.03 ]
LIFE 2002 188/4588 198/4605 74.1 % 0.95 [ 0.78, 1.16 ]
Total (95% CI) 4946 5005 100.0 % 0.90 [ 0.76, 1.06 ]
Total events: 236 (Beta-blocker), 271 (RAS inhibitor)
Heterogeneity: Chi2 = 1.73, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor, Outcome 4
Cardiovascular death.
Review: Beta-blockers for hypertension
Comparison: 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome: 4 Cardiovascular death
Study or subgroup Beta-blocker RAS inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UKPDS-39-1998 32/358 47/400 17.8 % 0.76 [ 0.50, 1.16 ]
AASK 2002 4/441 2/436 0.8 % 1.98 [ 0.36, 10.74 ]
LIFE 2002 234/4588 204/4605 81.4 % 1.15 [ 0.96, 1.38 ]
Total (95% CI) 5387 5441 100.0 % 1.09 [ 0.92, 1.29 ]
Total events: 270 (Beta-blocker), 253 (RAS inhibitor)
Heterogeneity: Chi2 = 3.56, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor, Outcome 5 Total
cardiovascular disease.
Review: Beta-blockers for hypertension
Comparison: 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome: 5 Total cardiovascular disease
Study or subgroup Beta-blocker RAS inhibitor Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Angiotensin-converting enzyme inhibitors
UKPDS-39-1998 74/358 106/400 38.7 % 0.78 [ 0.60, 1.01 ]
AASK 2002 13/441 11/436 12.7 % 1.17 [ 0.53, 2.58 ]
Subtotal (95% CI) 799 836 51.4 % 0.81 [ 0.63, 1.04 ]
Total events: 87 (Beta-blocker), 117 (RAS inhibitor)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.098)
2 Angiotensin receptor blockers
LIFE 2002 588/4588 508/4605 48.6 % 1.16 [ 1.04, 1.30 ]
Subtotal (95% CI) 4588 4605 48.6 % 1.16 [ 1.04, 1.30 ]
Total events: 588 (Beta-blocker), 508 (RAS inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0084)
Total (95% CI) 5387 5441 100.0 % 1.00 [ 0.72, 1.38 ]
Total events: 675 (Beta-blocker), 625 (RAS inhibitor)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.64, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 6.72, df = 1 (P = 0.01), I2 =85%
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Analysis 4.6. Comparison 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor, Outcome 6
Withdrawal due to adverse effects.
Review: Beta-blockers for hypertension
Comparison: 4 Beta-blocker versus renin-angiotensin system (RAS) inhibitor
Outcome: 6 Withdrawal due to adverse effects
Study or subgroup Beta-blocker RAS inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UKPDS-39-1998 125/358 88/400 12.2 % 1.59 [ 1.26, 2.00 ]
LIFE 2002 826/4588 599/4605 87.8 % 1.38 [ 1.26, 1.52 ]
Total (95% CI) 4946 5005 100.0 % 1.41 [ 1.29, 1.54 ]
Total events: 951 (Beta-blocker), 687 (RAS inhibitor)
Heterogeneity: Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 7.50 (P < 0.00001)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Previous systematic reviews of beta-blockers as first-line hypertension therapy
Identification Comparison Trials included Comments
Psaty 1997 Beta-blocker vs placebo MRC 1985; MRCOA 1992; Coope
1986; STOP 1991 trials
STOP 1991 classified as beta-
blocker trial as 68% in active group
were taking a beta-blocker
Messerli 1998 Beta-blocker vs placebo in older peo-
ple
Coope 1986; MRCOA 1992 The review concluded that beta-
blockers should not be used in el-
derly people with hypertension
Wright 1999 Beta-blocker vs diuretic Berglund 1981; HAPPHY 1987;
MRC 1985; MRCOA 1992; VA
COOP 1982
IPPPSH not included because 67%
of participants taking beta-blocker
were taking a diuretic
Wright 2000 Beta-blocker vs placebo MRC 1985; MRCOA 1992 Coope 1986 and STOP excluded be-
cause of high use of diuretic
Carlberg 2004 Atenolol vs placebo, and atenolol vs
other antihypertensive drugs
Placebo: Coope 1986; MRCOA
1992; Dutch TIA 1993; TEST
1995)
Included trials in which only a pro-
portion (> 50%) of participants
were assigned to start treatment with
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Table 1. Previous systematic reviews of beta-blockers as first-line hypertension therapy (Continued)
Other antihypertensive drugs: HAP-
PHY
1987; MRCOA 1992; UKPDS-39-
1998; LIFE 2002; ELSA 2002
atenolol
NICE 2004 Beta-blockers vs placebo, thiazide
diuretics, calcium-channel blockers,
ACE inhibitors, and angiotensin re-
ceptor blockers
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; MRCOA 1992; Dutch
TIA 1993; TEST 1995; STOP-2
1999
Thiazide diuretics: MRC 1985;
HAPPHY 1987; MAPHY 1988;
MRCOA 1992
Calcium-channel blockers:
CONVINCE 1998; STOP-2 1999;
NORDIL 2000; ELSA 2002; IN-
VEST 2003
ACE inhibitors: CAPP 1999;
STOP-2 1999
Angiotensin receptor blockers: LIFE
2002
IncludedMAPPHYwhich is a subset
of HAPPHY study. Included some
studies in which only a proportion
of participants were assigned to start
treatment on a beta-blocker
Lindhom 2005 Beta-blocker vs placebo, and beta-
blocker vs other antihypertensive
drugs
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; MRCOA 1992; Dutch
TIA 1993; TEST 1995
Other antihypertensive
drugs: Berglund 1981; MRC 1985;
HAPPHY 1987; STOP 1991; MR-
COA1992; Yurenev 1992; UKPDS-
39-1998; STOP-2 1999; NORDIL
2000; LIFE 2002; ELSA 2002;
CONVINCE 2003; ASCOT 2005
Included trials in which only a pro-
portion (> 50%) of participants were
assigned to start treatment with a
beta-blocker
Bradley 2006 Beta-blocker vs placebo, diuret-
ics, calcium-channel blockers, and
renin-angiotensin system inhibitors
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; MRCOA 1992
Diuretics: Berglund
1981; VACOOP1982; MRC 1985;
HAPPHY 1987; MRCOA 1992
Calcium-channel blockers: AASK
2002; ELSA 2002; INVEST 2003;
ASCOT 2005
Renin-angiotensin system
inhibitors: UKPDS-39-1998; AASK
2002; LIFE 2002
Excluded Dutch TIA 1993 and
TEST 1995 because not all partici-
pants in these 2 trials were had hy-
pertension
Khan 2006 Beta-blocker vs placebo, and beta-
blocker vs other antihypertensive
drugs
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; MRCOA 1992; Dutch
TIA 1993; TEST 1995
Other antihypertensive drugs:
Berglund 1981; MRC 1985; HAP-
PHY 1987; STOP 1991; MRCOA
Included trials in which only a pro-
portion (> 50%) of participants were
assigned to start treatment with a
beta-blocker
81Beta-blockers for hypertension (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Previous systematic reviews of beta-blockers as first-line hypertension therapy (Continued)
1992; Yurenev 1992; UKPDS-39-
1998; STOP-2 1999; CAPP 1999;
NORDIL 2000; LIFE 2002; ELSA
2002; CONVINCE 2003; ASCOT
2005
NICE 2006 Beta-blockers vs thiazide diuretics,
calcium-channel blockers, ACE in-
hibitors, and angiotensin receptor
blockers
Thiazide diuretics: MRC 1985;
HAPPHY 1987; MRCOA 1992
Calcium-channel blockers: ASCOT
2005; ELSA 1992; INVEST 2003
ACE inhibitors: no studies meeting
criteria
Angiotensin receptor blockers: LIFE
2002
UpdatedNICE 2004 review by eval-
uating head-to-head trials only. AS-
COT new study added and ex-
cluded CONVINCE; NORDIL;
and CAPP due to confounded use
Dahlöf 2007 Beta-blockers with or without di-
uretics vs placebo or no treatment
Coope 1986; MRC 1985; MRCOA
1992; STOP 1991; UKPDS-39
IPPPSH 1985 not included. STOP
1991 included because > 85% of
participants on active treatment re-
ceived beta-blocker as first-line or
second-line therapy. Regarded the
’control group’ in the UKPDS-39
as placebo, even though the group
permitted antihypertensive therapy
(other than
ACE inhibitors and beta-blockers),
because the target for blood pressure
reduction was not as low as in the
beta-blocker group
Wright 2009 Beta-blocker vs placebo MRC 1985; MRCOA 1992; Dutch
TIA 1993; TEST 1995; UKPDS-39
1998
IPPPSH 1985 and Coope 1986 ex-
cluded because of high use of diuret-
ics in beta-blocker group. UKPDS-
39 included using ’less tight control
group’ as placebo, but participants
took antihypertensive treatments for
57% of total person-years
Wiysonge 2012 Beta-blocker vs placebo, diuret-
ics, calcium-channel blockers, and
renin-angiotensin system inhibitors
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; MRCOA 1992
Diuretics (Berglund
1981; VACOOP1982; MRC 1985;
HAPPHY 1987; MRCOA 1992
Calcium-channel blockers: AASK
2002; ELSA 2002; INVEST 2003;
ASCOT 2005
Renin-angiotensin system
inhibitors: UKPDS-39-1998; AASK
2002; LIFE 2002
Previously published version of this
systematic review
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Table 1. Previous systematic reviews of beta-blockers as first-line hypertension therapy (Continued)
Kuyper 2014 Beta-blocker vs placebo, and beta-
blocker vs other antihypertensive
drugs
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; STOP 1991; MRCOA
1992; Dutch TIA 1993; TEST 1995
Other antihypertensive drugs:
Berglund 1981; MRC 1985; HAP-
PHY 1987; STOP 1991; MRCOA
1992; Yurenev 1992; UKPDS-39-
1998; STOP-2 1999; CAPP 1999;
NORDIL 2000; LIFE 2002; ELSA
2002; CONVINCE 2003; ASCOT
2005
Compared the efficacy of atenolol vs
non-atenolol beta-blockers in clini-
cal trials enrolling young (aged < 60
years) and older people with hyper-
tension
The review concluded that atenolol
should not be used in
older people with hypertension but
class effect uncertain, and beta-
blockers reasonable option for the
young
Wiysonge 2017 Beta-blocker vs placebo, diuret-
ics, calcium-channel blockers, and
renin-angiotensin system inhibitors
Placebo: IPPPSH1985; MRC 1985;
Coope 1986; MRCOA 1992
Diuretics: Berglund
1981; VACOOP1982; MRC 1985;
HAPPHY 1987; MRCOA 1992
Calcium-channel blockers: AASK
2002; ELSA 2002; INVEST 2003;
ASCOT 2005
Renin-angiotensin system
inhibitors: UKPDS-39-1998; AASK
2002; LIFE 2002
Current systematic review
ACE: angiotensin-converting enzyme.
Table 2. Effect of beta-blockers on lowering of blood pressure
Trial identification Beta-blocker Comparison drug Baseline BP (SBP/DBP;
mmHg)
Mean BP difference
(SBP/DBP)*
Beta-blocker vs placebo/no treatment
Coope 1986 Atenolol No treatment 196.7/99.7 -18.0/-11.0
MRCOA 1992 Atenolol Placebo 184.0/91.0 -13.0/-7.0
MRC 1985 Propranolol Placebo 162.0/98.5 -9.5/-5.0
IPPPSH 1985 Oxprenolol Placebo 173.2/107.9 -4.1/-1.5
Beta-blocker vs diuretic
MRCOA 1992 Atenolol Diuretic 184.0/91.0 +1.0/-0.5
HAPPHY 1987 Atenolol or metoprolol or
propranolol
Diuretic 166.0/107.9 0.0/-1.0
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Table 2. Effect of beta-blockers on lowering of blood pressure (Continued)
Berglund 1981 Propranolol Diuretic 174.0/105.5 -4.0/+2.0
VA COOP 1982 Propranolol Diuretic 146.3/101.5 +7.0/+1.6
MRC 1985 Propranolol Diuretic 162.0/98.5 +3.5/+1.0
Beta-blocker vs calcium-channel blocker
ELSA 2002 Atenolol Calcium-channel blocker 163.1/101.3 +0.2/-0.1
INVEST 2003 Atenolol Calcium-channel blocker 150.8/87.2 +0.3/+0.2
ASCOT 2005 Atenolol Calcium-channel blocker 164.0/94.7 +1.6/+1.8
AASK 2002 Metoprolol Calcium-channel blocker 150.0/96.0 +2.0/0.0
Beta-blocker vs renin-angiotensin system inhibitor
UKPDS-39-1998 Atenolol Renin-angiotensin
system inhibitor (ACE in-
hibitor)
159.0/93.0 -1.0/-1.0
LIFE 2002 Atenolol Renin-angiotensin
system inhibitor (ARB)
174.5/97.7 +1.1/-0.2
AASK 2002 Metoprolol Renin-angiotensin
system inhibitor (ACE in-
hibitor)
150.0/96.0 0.0/-1.0
* ’Minus sign’ means beta-blocker group had lower BP, and ’plus sign’ means beta-blocker group had higher BP than control group.
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; BP: blood pressure; DBP: diastolic blood pressure; SBP:
systolic blood pressure.
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A P P E N D I C E S
Appendix 1. 2015 search strategy
Ovid MEDLINE(R) 1946 to Present with Daily Update
Search Date: 19 January 2015
--------------------------------------------------------------------------------
1 exp adrenergic beta-antagonists/ (76928)
2 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or
bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or
bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or
exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol
or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol
or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or
primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol
or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).mp.
(73611)
3 (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw. (86331)
4 or/1-3 (139776)
5 hypertension/ (192862)
6 hypertens$.tw. (304808)
7 exp blood pressure/ (247717)
8 (blood pressure or blood pressure).mp. (350302)
9 or/5-8 (589677)
10 randomized controlled trial.pt. (381216)
11 controlled clinical trial.pt. (88387)
12 randomi?ed.ab. (334664)
13 placebo.ab. (147683)
14 drug therapy.fs. (1727364)
15 randomly.ab. (198880)
16 trial.ab. (288170)
17 groups.ab. (1274045)
18 or/10-17 (3261120)
19 animals/ not (humans/ and animals/) (3879559)
20 18 not 19 (2775676)
21 4 and 9 and 20 (19415)
22 21 and (2013$ or 2014$ or 2015$).ed. (674)
23 remove duplicates from 22 (663)
Embase <1974 to 2015 January 16>
Search Date: 19 January 2015
--------------------------------------------------------------------------------
1 exp beta adrenergic receptor blocking agent/ (243970)
2 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or
bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or
bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or
exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol
or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol
or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or
primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol
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or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).mp.
(178474)
3 (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw. (104425)
4 or/1-3 (294052)
5 exp hypertension/ (510805)
6 hypertens$.tw. (448067)
7 exp blood pressure/ (413025)
8 blood pressure o bloodpressure.mp. (0)
9 or/5-8 (911302)
10 randomized controlled trial/ (358482)
11 crossover procedure/ (41032)
12 double-blind procedure/ (119385)
13 (randomi?ed or randomly).tw. (749012)
14 (crossover$ or cross-over$).tw. (73500)
15 placebo$.ab. (204404)
16 (doubl$ adj blind$).tw. (152473)
17 assign$.ab. (245912)
18 allocat$.ab. (86645)
19 or/10-18 (1145599)
20 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5518138)
21 19 not 20 (995733)
22 4 and 9 and 21 (11880)
23 22 and (2013$ or 2014$ or 2015$).em. (1164)
24 remove duplicates from 23 (1150)
Cochrane Central Register of Controlled Trials on Wiley <Issue 1, 2015> via Cochrane Register of Studies Online
Search Date: 19 January 2015
--------------------------------------------------------------------------------
#1:(adrenergic beta-antagonist*) - 3953
#2: (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or
bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or
bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or
exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol
or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol
or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or
primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or
spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol) - 14056
#3: beta near2 (adrenergic* or antagonist* or block* or receptor*) - 11011
#4: #1 OR #2 OR #3 - 18403
#5: antihypertens* or hypertens* - 35486
#6: (“blood pressure” or bloodpressure) - 46400
#7: #5 OR #6 - 63228
#8: #4 AND #7 - 9332
#9: 01/10/2013 TO 19/01/2015:CD - 123974
#10: #8 AND #9 - 793
***************************
Hypertension Group Specialised Register
Search Date: 19 January 2015
--------------------------------------------------------------------------------
1 (adrenergic beta-antagonist*)
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2 (beta blocker*)
3 (beta adrenergic block*)
4 (adrenergic beta receptor block*)
5 (beta adrenergic receptor block*)
6 #1 OR #2 OR #3 OR #4 OR #5
7 (hypertens*)
8 #6 AND #7
9 #8 AND (RCT OR Review OR Meta-Analysis) (1782)
***************************
ClinicalTrials.gov (via Cochrane Register of Studies)
Search Date: 19 January 2015
--------------------------------------------------------------------------------
Search terms: randomized
Study type: Interventional
Conditions: hypertension
Interventions: “adrenergic beta-antagonist” OR “adrenergic beta-antagonists” OR “beta blocker” OR “beta blockers”
Outcome Measures: blood pressure
First received: 1/10/2013 to 19/1/2015 (9)
***************************
Appendix 2. 2016 Search strategy
Ovid MEDLINE(R) 1946 to Present with Daily Update
Search Date: 14 June 2016
--------------------------------------------------------------------------------
1 exp adrenergic beta-antagonists/ (79179)
2 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or
bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or
bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or
exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol
or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol
or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or
primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol
or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).mp.
(75673)
3 (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw. (90482)
4 or/1-3 (145660)
5 hypertension/ (210798)
6 hypertens$.tw. (330792)
7 exp blood pressure/ (264762)
8 (blood pressure or blood pressure).mp. (373969)
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9 or/5-8 (633729)
10 randomized controlled trial.pt. (420851)
11 controlled clinical trial.pt. (91010)
12 randomi?ed.ab. (379711)
13 placebo.ab. (159968)
14 drug therapy.fs. (1873762)
15 randomly.ab. (223574)
16 trial.ab. (328035)
17 groups.ab. (1409370)
18 or/10-17 (3572728)
19 animals/ not (humans/ and animals/) (4231241)
20 18 not 19 (3046252)
21 4 and 9 and 20 (20003)
22 21 and (2015$ or 2016$).ed. (528)
23 remove duplicates from 22 (498)
***************************
Cochrane Central Register of Controlled Trials on Wiley <2016, Issue 6> via Cochrane Register of Studies Online
Search Date: 14 June 2016
--------------------------------------------------------------------------------
#1MESH DESCRIPTOR Adrenergic beta-Antagonists EXPLODE ALL TREES9429
#2adrenergic beta-antagonist*4072
#3(acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or
bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or
bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or
exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol
or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol
or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or
primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or
spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol)14950
#4beta near2 (adrenergic* or antagonist* or block* or receptor*)12693
#5#1 OR #2 OR #3 OR #420606
#6antihypertens* or hypertens*40964
#7blood pressure or bloodpressure52553
#8#6 OR #772648
#9#5 AND #810268
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#1001/01/2015 TO 14/06/2016:CD AND 01/01/2015 TO 14/06/2016:CD107219
#11#9 AND #10558
***************************
Embase <1974 to 2016 June 13>
Search Date: 14 June 2016
--------------------------------------------------------------------------------
1 exp beta adrenergic receptor blocking agent/ (257952)
2 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or
bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or
bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or
exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol
or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol
or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or
primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol
or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).mp.
(186549)
3 (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw. (112699)
4 or/1-3 (312536)
5 exp hypertension/ (577705)
6 hypertens$.tw. (508421)
7 exp blood pressure/ (464921)
8 blood pressure o bloodpressure.mp. (0)
9 or/5-8 (1027859)
10 randomized controlled trial/ (408424)
11 crossover procedure/ (47399)
12 double-blind procedure/ (131405)
13 (randomi?ed or randomly).tw. (880104)
14 (crossover$ or cross-over$).tw. (82444)
15 placebo$.ab. (231893)
16 (doubl$ adj blind$).tw. (169466)
17 assign$.ab. (283020)
18 allocat$.ab. (102246)
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19 or/10-18 (1321527)
20 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5874427)
21 19 not 20 (1153534)
22 4 and 9 and 21 (12623)
23 22 and (2015$ or 2016$).em. (818)
24 remove duplicates from 23 (795)
***************************
Cochrane Hypertension Specialised Register
Search Date: Search Date: 14 June 2016
--------------------------------------------------------------------------------
#1 (adrenergic beta-antagonist*) (1506)
#2 (beta blocker*) (2211)
#3 (beta adrenergic block*) (247)
#4 (adrenergic beta receptor block*) (13)
#5 (beta adrenergic receptor block*) (1141)
#6 #1 OR #2 OR #3 OR #4 OR #5 (3838)
#7 RCT:DE (22671)
#8 (Review or Meta-Analysis):MISC2 (1147)
#9 #6 AND (#7 OR #8) (2176)
#10 (#9) AND (1/1/2015 TO 14/6/2016:CRSMODIFIED) (398)
***************************
ClinicalTrials.gov
Search Date: 14 June 2016
--------------------------------------------------------------------------------
Search terms: randomized
Study type: Interventional
Conditions: hypertension
Interventions: “adrenergic beta-antagonist” OR “adrenergic beta-antagonists” OR “beta blocker” OR “beta blockers”
Outcome Measures: blood pressure (95)
***************************
WH A T ’ S N E W
Last assessed as up-to-date: 13 December 2016.
Date Event Description
12 January 2017 New search has been performed Up to date search. No new studies met the inclusion
criteria
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(Continued)
12 January 2017 New citation required but conclusions have not changed Conclusions have been reworded and there is a change
in authorship and author affiliations
H I S T O R Y
Protocol first published: Issue 3, 1998
Review first published: Issue 1, 2007
Date Event Description
16 November 2012 Amended New search fromDecember 2011 to November 2012.
27 August 2012 Amended updated author affiliations
9 July 2012 New search has been performed New search from June 2006 to December 2011. No
new studies met the inclusion criteria. The Risk of
Bias table has been updated for all included studies
and 4 Summary of findings tables have been added
to the updated review. In the 2007 version there were
unintended errors in the data entered for withdrawals
due to side effects for the two UK Medical Research
Council trials (MRC 1985, MRCOA 1992), which
led to the erroneous conclusion that patients on beta-
blockers weremore likely to discontinue treatment due
to side effects than those on diuretics. The corrected
data, in this update, show no significant differences in
withdrawals due to side effects between beta-blockers
and diuretics. The overall message in the conclusions
has not changed
9 July 2012 New citation required but conclusions have not
changed
New citation due to update
13 August 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
CSW and HB screened the search output, selected studies, assessed the risk of bias, and extracted data. At each stage, the two review
authors resolved differences by discussion and consensus; with arbitration by JV.
CW conducted the analyses.
All review authors read and approved the final version before submission.
CSW and HB contributed equally to this review and share first authorship.
D E C L A R A T I O N S O F I N T E R E S T
We have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of this
systematic review.
S O U R C E S O F S U P P O R T
Internal sources
• South African Medical Research Council (CSW), South Africa.
• Stellenbosch University (CSW, JV), South Africa.
• University of the Western Cape (HB), South Africa.
• University of Cape Town (BMM, LHO), South Africa.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have decided to have clearly defined strict eligibility criteria regarding duration of treatment, which we have now set at one year or
more on trial medications. In the protocol and initial version of the review published in 2007, duration of treatment was not included
as a criterion for eligibility. We have now used the ’Risk of bias’ tool as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). This tool was not yet developed when the protocol was written.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenergic beta-Antagonists [adverse effects; ∗therapeutic use]; Angiotensin Receptor Antagonists [therapeutic use]; Antihypertensive
Agents [adverse effects; ∗therapeutic use]; Atenolol [therapeutic use]; Calcium Channel Blockers [therapeutic use]; Coronary Disease
[prevention & control]; Diuretics [therapeutic use]; Heart Arrest [prevention & control]; Hypertension [∗drug therapy; mortality];
Randomized Controlled Trials as Topic; Stroke [prevention & control]
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MeSH check words
Adult; Aged; Humans; Middle Aged
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